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A B S T R A C T
Background
Although smoking cessation is currently the only guaranteed way to reduce the harm caused by tobacco smoking, a reasonable secondary
tobacco control approach may be to try and reduce the harm from continued tobacco use amongst smokers unable or unwilling to quit.
Possible approaches to reduce the exposure to toxins from smoking include reducing the amount of tobacco used, and using less toxic
products, such as pharmaceutical, nicotine and potential reduced-exposure tobacco products (PREPs), as an alternative to cigarettes.
Objectives
To assess the effects of interventions intended to reduce the harm to health of continued tobacco use, we considered the following specific
questions: do interventions intended to reduce harm have an effect on long-term health status?; do they lead to a reduction in the number
of cigarettes smoked?; do they have an effect on smoking abstinence?; do they have an effect on biomarkers of tobacco exposure?; and
do they have an effect on biomarkers of damage caused by tobacco?
Search methods
We searched the Cochrane Tobacco Addiction Group Trials Register (CRS) on the 21st October 2015, using free-text and MeSH terms for
harm reduction, smoking reduction and cigarette reduction.
Selection criteria
Randomized or quasi-randomized controlled trials of interventions to reduce the amount smoked, or to reduce harm from smoking by
means other than cessation. We include studies carried out in smokers with no immediate desire to quit all tobacco use. Primary outcomes
were change in cigarette consumption, smoking cessation and any markers of damage or benefit to health, measured at least six months
from the start of the intervention.
Data collection and analysis
We assessed study eligibility for inclusion using standard Cochrane methods. We pooled trials with similar interventions and outcomes (>
50% reduction in cigarettes a day (CPD) and long-term smoking abstinence), using fixed-effect models. Where it was not possible to meta-
analyse data, we summarized findings narratively.
Main results
Twenty-four trials evaluated interventions to help those who smoke to cut down the amount smoked or to replace their regular cigarettes
with PREPs, compared to placebo, brief intervention, or a comparison intervention. None of these trials directly tested whether harm re-
duction strategies reduced the harms to health caused by smoking. Most trials (14/24) tested nicotine replacement therapy (NRT) as an
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intervention to assist reduction. In a pooled analysis of eight trials, NRT significantly increased the likelihood of reducing CPD by at least
50% for people using nicotine gum or inhaler or a choice of product compared to placebo (risk ratio (RR) 1.75, 95% confidence interval
(CI) 1.44 to 2.13; 3081 participants). Where average changes from baseline were compared for different measures, carbon monoxide (CO)
and cotinine generally showed smaller reductions than CPD. Use of NRT versus placebo also significantly increased the likelihood of ulti-
mately quitting smoking (RR 1.87, 95% CI 1.43 to 2.44; 8 trials, 3081 participants; quality of the evidence: low). Two trials comparing NRT
and behavioural support to brief advice found a significant effect on reduction, but no significant effect on cessation. We found one trial
investigating each of the following harm reduction intervention aids: bupropion, varenicline, electronic cigarettes, snus, plus another of
nicotine patches to facilitate temporary abstinence. The evidence for all five intervention types was therefore imprecise, and it is unclear
whether or not these aids increase the likelihood of smoking reduction or cessation. Two trials investigating two different types of behav-
ioural advice and instructions on reducing CPD also provided imprecise evidence. Therefore, the evidence base for this comparison is in-
adequate to support the use of these types of behavioural advice to reduce smoking. Four studies of PREPs (cigarettes with reduced levels
of tar, carbon and nicotine, and in one case delivered using an electronically-heated cigarette smoking system) showed some reduction
in exposure to some toxicants, but it is unclear whether this would substantially alter the risk of harm. We judged the included studies to
be generally at a low or unclear risk of bias; however, there were some ratings of high risk, due to a lack of blinding and the potential for
detection bias. Using the GRADE system, we rated the overall quality of the evidence for our cessation outcomes as ‘low’ or ‘very low’, due
to imprecision and indirectness. A ‘low’ grade means that further research is very likely to have an important impact on our confidence in
the estimate of effect and is likely to change the estimate. A ‘very low’ grade means we are very uncertain about the estimate.
Authors' conclusions
People who do not wish to quit can be helped to cut down the number of cigarettes they smoke and to quit smoking in the long term,
using NRT, despite original intentions not to do so. However, we rated the evidence contributing to the cessation outcome for NRT as 'low'
by GRADE standards. There is a lack of evidence to support the use of other harm reduction aids to reduce the harm caused by continued
tobacco smoking. This could simply be due to the lack of high-quality studies (our confidence in cessation outcomes for these aids is rated
'low' or 'very low' due to imprecision by GRADE standards), meaning that we may have missed a worthwhile effect, or due to a lack of
effect on reduction or quit rates. It is therefore important that more high-quality RCTs are conducted, and that these also measure the
long-term health effects of treatments.
P L A I N   L A N G U A G E   S U M M A R Y
Can smokers be helped to reduce the harm caused by cigarette smoking by smoking fewer cigarettes or using different tobacco
products?
Background
The best thing to do to reduce the harms caused by smoking is to quit, but some people may not want to do this or may feel that they
are unable to stop smoking completely. Cutting down the number of cigarettes smoked daily or using different tobacco products, such
as chewing tobacco or low-tar cigarettes, may reduce some of the harm caused by smoking. It may also help people to stop smoking
completely in the long term. On the other hand, reducing smoking or using other tobacco products may not improve health and could
reduce a person's motivation to quit smoking altogether. It is important that we review the evidence to find out whether these approaches
could help smokers who do not want to or cannot quit to reduce the harm caused by their smoking. We were mainly interested in whether
these approaches improved the health of smokers, but also looked at smoking reduction and quitting rates.
Study characteristics
We found 20 randomised controlled trials that tested ways to help people to cut down the number of cigarettes they smoked. Some of these
just advised smokers to smoke less, but most also provided them with a product to help them cut down: nicotine replacement therapy
(NRT), varenicline, bupropion, electronic cigarettes (ecigs), or snus (a form of smokeless, oral tobacco). We also found four randomized
controlled trials that tested the effects of using cigarettes designed to reduce the damage caused by smoking: reduced tar, carbon or
nicotine cigarettes. Most of the studies used NRT to help people to reduce their smoking. All of the studies included people who were not
planning to quit smoking soon. The research is current to October 2015.
Key results
Eight studies (with 3081 smokers) found that using NRT roughly doubled the likelihood of halving the number of cigarettes smoked each
day, compared to using a placebo. Using NRT in this way also nearly doubled the likelihood of quitting completely. One trial each test-
ed bupropion, varenicline, ecigs and snus to help reduce the harms caused by smoking, and there was no evidence that any of these
treatments helped smokers to reduce the number of cigarettes they were smoking each day. This may be because there has not yet been
enough research into these methods. Only one of the trials testing cigarettes designed to reduce risk measured their effect on the number
of people quitting smoking. It found that people were not more likely to quit smoking if they used reduced-nicotine cigarettes than if they
smoked their usual cigarettes. We did not find any trials which reported the long-term health effects of the treatments, and so it remains
uncertain how much health benefit there is from reducing the number of cigarettes smoked each day or smoking cigarettes designed to
be less harmful.
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Quality of evidence
The tobacco industry funded three of the included studies of cigarettes designed to reduce risk. None of the studies looked at whether
there had been a long-term change in the health of the users. We rate the quality of the evidence looking at how many people quit smoking
as 'low' or 'very low', generally because the findings are based on a small number of studies. We need more studies to investigate methods
of reducing the harm caused by continued smoking. These need to measure the health of the users over a long period.
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Summary of findings for the main comparison.   Interventions to reduce the harms caused by smoking in people who cannot or do not want to quit
smoking
Interventions to reduce the harms caused by continued smoking
Patient or population: Smokers who cannot or do not want to quit smoking
Setting: Varied
Intervention: Various harm reduction aids (NRT, behavioural advice, bupropion, varenicline, ecigs, snus, low-nicotine cigarettes)
Comparison: Various controls (placebo, usual care, brief advice, self-help, regular cigarettes)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
control
Risk with
harm reduc-
tion aid
Relative effect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Long-term change in health status We found no studies that re-
ported this primary outcome
Not applicable (0 RCTs) Not applicable  
Study populationCessation: NRT vs placebo
follow-up: 12 to 24 months
5 per 100 10 per 100
(7 to 13)
RR 1.87
(1.43 to 2.44)
3081
(8 RCTs)
⊕⊕⊝⊝
LOW 1
 
Study populationCessation: Bupropion vs. placebo
follow up: 6 months
5 per 100 7 per 100
(4 to 13)
RR 1.27
(0.67 to 2.40)
594
(1 RCT)
⊕⊕⊝⊝
LOW 2
 
Study populationCessation: Varenicline vs placebo
follow-up: 6 months
7 per 100 14 per 100
(6 to 32)
RR 1.95
(0.86 to 4.40)
218
(1 RCT)
⊕⊕⊝⊝
LOW 2
 
Study populationCessation: Ecigs vs placebo
follow-up: 12 months
4 per 100 11 per 100
(4 to 31)
RR 2.75
(0.97 to 7.76)
300
(1 RCT)
⊕⊕⊝⊝
LOW 2
 
Cessation: Snus vs placebo
follow-up: 6 months
Study population RR 3.06
(0.84 to 11.08)
319
(1 RCT)
⊕⊕⊝⊝
LOW 2
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2 per 100 6 per 100
(2 to 21)
Study populationCessation: Low-nicotine cigarettes vs regular
cigarettes
follow-up: 6 months 2 per 100 3 per 100
(0 to 27)
RR 1.38
(0.13 to 14.79)
135
(1 RCT)
⊕⊝⊝⊝
VERY LOW 2 3
 
Study populationCessation: Behavioural reduction advice vs
health mailings
follow-up: 12 months 4 per 100 7 per 100
(3 to 17)
RR 1.49
(0.59 to 3.76)
320
(1 RCT)
⊕⊝⊝⊝
VERY LOW 2 4
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; NRT: nicotine replacement therapy; Ecigs: electronic cigarettes
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1Downgraded two levels due to imprecision. Small number of events (< 300), and wide confidence intervals.
2Downgraded two levels due to imprecision. Small number of events (< 300), and small number of studies.
3Downgraded one level due to risk of bias. The study was intentionally unblinded to simulate a 'real world' situation, but this provides potential for detection bias. There were
more dropouts in the intervention arm than the control arm, due to "not liking the cigarettes".
4Downgraded one level due to indirectness. Participants were awaiting surgery and so a very specific population, which may differ from the general population.
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B A C K G R O U N D
Description of the condition
The morbidity and mortality associated with smoking is well estab-
lished. People who stop smoking can reduce their risk of develop-
ing smoking-related diseases (Anthonisen 2005; Doll 2004), so the
primary strategy for reducing harm due to tobacco smoking must
be to encourage cessation. However, despite the fact that most
people who smoke say that they want to stop, the prevalence of
smoking is declining very slowly, even in those countries where to-
bacco control policies are well developed, and in some cases preva-
lence is still rising (Bilano 2015). In 2005 the World Health Organi-
zation (WHO) Framework Convention on Tobacco Control formal-
ized a global commitment to reduce tobacco use worldwide and
make tobacco control a global health priority (WHO 2003). In 2014,
based on this Framework, the WHO member states went on to agree
a target of a 30% relative reduction in tobacco use worldwide by
2025 (WHO 2013). However, based on the actual decline in smok-
ing prevalence, predictions of trends to 2025 suggest that only 25%
of countries worldwide will be likely to experience this decrease
in smoking men, and only 52% will be likely to experience this de-
crease in smoking women from 2010 to 2025. This means fewer
than half of countries globally are likely to meet the WHO targets,
and this issue is not limited only to low- and middle-income coun-
tries (Bilano 2015). Although it is important to continue to motivate
and assist people to quit, it may therefore be reasonable to seek
ways to reduce the harm from continued smoking for people who
are not ready to or cannot quit, as a secondary strategy to improve
global health.
Description of the intervention
There are multiple approaches that may have potential for harm
reduction for people who do not want to give up tobacco or nico-
tine use completely. Shiffman 2002 has provided a catalogue of
these with a conceptual structure of their characteristics. They cov-
er many different intended intermediate effects and mechanisms.
They also differ in the likely ease of the behaviour change needed to
adopt them and related appeal to smokers, and their expected pop-
ulation risk. Shiffman 2002 categorizes tobacco harm reduction in-
to the following four approaches:
1. Methods to establish and adhere to tobacco abstinence, as ac-
knowledged above;
2. The use of tobacco products in a way or in a form that is less
harmful than traditional products;
3. The use of pharmaceutical products to reduce tobacco use or
the harm caused; and
4. Changes in behaviours that will reduce harm.
Categories two to four are the subject of this review.
Products that fall within the second category are referred to as po-
tential reduced-exposure products (PREPs), which are:
"(a) modified tobacco products that contain reduced levels of one
or more toxins (for example, cigarettes with reduced tobacco-spe-
cific nitrosamines through new curing processes, the addition of
catalysts to reduce polycyclic aromatic hydrocarbon carcinogens
produced by smoke, the use of genetically modified plants to re-
duce nicotine or nitrosamines, or the use of filters to selectively re-
duce toxicants), (b) cigarette-like devices, such as those that heat
rather than burn tobacco, and (c) oral non-combustible products,
such as snus" (Hatsukami 2005a).
Some oral smokeless tobacco products have been estimated to
be approximately 90% less harmful than smoking cigarettes (Levy
2004). Research on alternative tobacco products has largely been
conducted within the tobacco industry and has generally attempt-
ed to modify the characteristics of existing tobacco-containing
products, or to design new types of commercial tobacco prod-
ucts, to make tobacco use less dangerous. Very large, independent-
ly-conducted, long-term trials are required to fully evaluate their
effects (Murrelle 2010).
The use of pharmaceutical products to reduce harm could, for ex-
ample, refer to using any of the existing pharmacotherapies already
available to help people to quit smoking, such as nicotine replace-
ment therapy (NRT), varenicline or bupropion, to reduce tobacco
consumption. There is variation in whether NRT is licensed for use
as a reduction aid across countries; for example, the US Food and
Drug Administration (FDA) have not approved the use of NRT for
smokers who wish to cut down the amount they smoke without
wanting to quit. However, the Medicines and Healthcare Regulato-
ry Authority (MHRA) in the UK have licensed it for this purpose. Fi-
nally, "changes in behaviors that will reduce harm" applies to be-
haviour change interventions such as reducing the number of cig-
arettes smoked each day (CPD), otherwise known as 'controlled
smoking', which could be carried out alongside the use of other
aids, such as PREPs or pharmaceutical products.
How the intervention might work
There are two major routes through which we would expect the
above harm reduction approaches to work: 1) by promoting subse-
quent smoking cessation, as a by-product of harm reduction (rather
than encouraging quitting specifically); and 2) by reducing the
health effects of smoking without quitting completely. There is evi-
dence that the smoking reduction potentially promoted by the ma-
jority of harm reduction approaches is associated with an increase
in subsequent cessation. A qualitative systematic review (Hughes
2006) of 19 observational studies and randomized controlled trials
(RCTs) showed no indication that CPD reduction had a negative im-
pact on future cessation; in fact, 16 of the 19 studies found reduc-
tion was associated with higher eventual quit rates.This association
may be because reduction increases self-efficacy, disrupts pharma-
cological conditioning or reduces dependence, or both. However,
there is also evidence that attempts at smoking reduction can be
undermined by other unconscious adjustments to smoking behav-
iour, for example taking longer, deeper puHs of a cigarette to main-
tain previous nicotine levels (Scherer 1999). Using an alternative
reduced-harm nicotine source (such as NRT, snus, electronic ciga-
rettes (ecigs)) to support behavioural reduction could help to com-
pensate for this, by reducing nicotine withdrawal and subsequent
cravings. In Sweden the use of snus as a cigarette substitute has
been credited for a reduction in smoking among men, which is as-
sociated with lower tobacco-related mortality rates in Sweden than
in other European countries (Ramstrom 2014). There is mixed evi-
dence for the effects of smoking reduction on disease and health
markers. For example, a systematic review reports that their largest
included study found a reduction in lung cancer risk in smokers
who reduced consumption compared with those who maintained
their smoking behaviour (Pisinger 2007); however, a later study
found no evidence of a reduction in risk (Hart 2013). There is some
evidence that smoking reduction can reduce biomarkers related to
Interventions to reduce harm from continued tobacco use (Review)
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the risk of cancer or carcinogen exposure, or both; however, it is un-
clear whether this reduces the incidence of cancer (Pisinger 2007).
Why it is important to do this review
Most evidence investigating the link between smoking reduction
and health currently comes from observational, epidemiological
studies, and there are issues with this. Firstly, because smoking is
generally measured at two time points and if the later one demon-
strates a lower rate than the initial one, it is assumed that smok-
ing reduction has been maintained throughout the follow-up pe-
riod, which may not be the case. Secondly, many of the studies
have not used biomarkers to validate smoking consumption, which
could mean that compensatory smoking (such as deeper puHs) is
not accounted for. Finally, many of these studies have not included
people who used alternative nicotine products to compensate for
smoking, which may impact on the success of reduction, and there-
fore on the associated changes in health risks (Begh 2015). The na-
ture of RCTs means that all of these factors can be controlled for
more effectively (although this is not always the case), and where
this has been done we can be more confident that results indicating
associations between reduction and health are causal. By review-
ing these studies, we can make a valuable contribution to the liter-
ature and to the debate surrounding harm reduction approaches.
However, the use of harm reduction strategies in relation to tobac-
co smoking is a controversial topic, which divides opinion. There
are concerns that encouraging people to reduce their smoking may
undermine their motivation to quit smoking in the long term, and
that this may encourage the tobacco industry to market 'reduced
risk' products and carry out biased research on their effectiveness
(Hatsukami 2004). The availability of ostensibly less harmful tobac-
co products could even lead never-smokers to start smoking, or ex-
smokers to relapse, in the belief that the risks are acceptable. These
are questions that cannot be answered by RCTs alone, and are out-
side the scope of this review; the results of this review should there-
fore be considered alongside research which investigates any po-
tential negative impact of promoting harm reduction.
Despite the ongoing debate regarding the promotion of tobacco
use harm reduction, in 2013 the UK National Institute for Health
and Care Excellence (NICE) published their first version of guidance
on how to offer harm reduction approaches to smokers unwilling
or unable to quit in one step, who may want to use a long-term
safer substitute for smoking, or may only be ready to reduce the
amount they smoke (NICE 2013). This guidance therefore recom-
mends some non-traditional interventions where the ultimate goal
is still to quit (reducing smoking to quit), but also recommends be-
havioural smoking reduction with or without the use of NRT, and
temporary abstinence with or without NRT for smokers who need
to stop smoking for a set period of time, for example, during work-
ing hours, a long-haul flight, or a hospital stay. The guidance high-
lights that the health benefits of smoking reduction, rates of relapse
and progression to stopping smoking among people who have opt-
ed to reduce the amount they smoke are still unclear, and that bet-
ter evidence is therefore still required to support and inform the
harm reduction approach. In addition, new products, such as ecigs,
that have the potential to be used in a harm-reduction capacity
have also become available since the last update of this review. Ev-
idence is needed to inform whether these harm reduction interven-
tions could be useful in reducing tobacco-related harm in smokers
who cannot, or do not wish to, quit.
O B J E C T I V E S
To assess the effects of interventions intended to reduce the harm
to health of continued tobacco use. We considered the following
specific questions:
• Do interventions intended to reduce harm have an effect on
long-term health status?• Do interventions intended to reduce harm lead to a reduction in
the number of cigarettes smoked?• Do interventions intended to reduce harm have an effect on
smoking abstinence?• Do interventions intended to reduce harm have an effect on bio-
markers of tobacco exposure?• Do interventions intended to reduce harm have an effect on bio-
markers of damage caused by tobacco?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized or quasi-randomized controlled trials.
Types of participants
People who smoke tobacco, but have no immediate intention to
quit all tobacco use. We included trials which did not assess moti-
vation if an aim was to reduce cigarette consumption, but not to
quit entirely.
Types of interventions
Interventions to reduce the amount smoked, or to reduce harm
from smoking by means other than cessation, including switching
to a potential reduced-exposure product (PREP), or making oth-
er changes to cigarette characteristics. We excluded interventions
where a reduction in the number of cigarettes smoked over a short
period, or a change in type of cigarette smoked (e.g. nicotine fad-
ing), was intended as a precursor to quitting completely.
We deemed studies eligible for inclusion if they compared these in-
terventions to any 'standard control', such as brief advice, no treat-
ment or placebo, or compared one type of harm reduction inter-
vention to another.
Types of outcome measures
Primary outcomes
The preferred primary outcome was long-term change in health
status, but we expected that this was unlikely to be assessed in
randomized trials. The most appropriate proxy indicator to demon-
strate a reduction in toxin intake from tobacco use, sufficient to
lead to a clinically useful long-term health benefit is not known
(Hatsukami 2005a). We have therefore considered and extracted
any attempt made to measure a health marker.
In the absence of better health indicators, we have also assessed
both the change in smoking rate from baseline and smoking ces-
sation as primary outcomes. For smoking reduction outcomes, we
preferred prolonged or continuous rates to point prevalence rates.
Where studies did not incorporate abstinent participants in their re-
duction rates we have done this for the purposes of our meta-analy-
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ses, as participants who have quit smoking have by definition re-
duced to zero. As there was no expectation that participants would
quit at the start of the intervention, we have favoured measures of
abstinence based on behaviour towards the end of the follow-up
period (i.e. point prevalence rates) over continuous or sustained
abstinence rates (Hughes 2003). We preferred biochemically-vali-
dated rates to self-reported rates for both reduction and cessation
outcomes. To be eligible for inclusion, a study had to report at least
one of these outcomes at least six months following baseline.
Secondary outcomes
We extracted information on any biochemical indicators of the
amount of tobacco use, and on adverse events when the interven-
tion being tested included the use of a pharmaceutical, nicotine- or
tobacco-based substitute for tobacco smoking.
Search methods for identification of studies
We searched the Cochrane Tobacco Addiction Group Trials Regis-
ter (CRS), which includes controlled trials and other evaluations of
interventions to change tobacco use behaviour, derived from sys-
tematic searches of the Cochrane Central Register of Controlled Tri-
als (CENTRAL), MEDLINE, Embase, PsycINFO. At the time of search
(21st October 2015) the Register included the results of searches of
CENTRAL (Issue 10, 2015); MEDLINE (via OVID) to update 20151012;
Embase (via OVID) to week 201541; PsycINFO (via OVID) to update
20151005.
The MeSH terms 'Harm reduction' and 'Risk reduction behavior'
were only introduced in 2003, so free-text searches were the main
method for identifying earlier relevant trials. Original terms used
were 'harm reduction', 'smoking reduction' 'reduce* smoking', 'to-
bacco harm', 'cigarette consumption near (reduction or reduce*)',
'controlled smoking'. Risk Assessment [MeSH], Harm reduction
[MeSH], Risk reduction behavior [MeSH]. The most up-to-date, full
search strategy for identifying studies for this review update in the
CRS is shown in Appendix 1.
We also searched the reference lists of studies found in the liter-
ature search and the metaRegister of controlled trials database
(www.isrctn.com/page/mrct) to October 2015.
Data collection and analysis
Selection of studies
Two authors (from AF, JHB, NLH, RB for this update; TL & previ-
ous author LS for previous versions) independently screened pa-
pers identified by the search strategy for possible relevance in two
stages (titles and abstracts, and full-text). Both authors discussed
any differences between them, and where necessary had recourse
to a third author.
Data extraction and management
Two authors (from AF, JHB, NLH, RB for this update; TL & previ-
ous author LS for previous versions) independently extracted data
from full-text papers deemed eligible for inclusion. We checked for
agreement, and discussed and resolved any differences within the
author team.
We collected the following information for each trial:
• Country and setting of intervention
• Method of participant recruitment and main inclusion criteria in
relation to motivation to change tobacco use• Other participant characteristics, including age, sex, previous
smoking habit, quit attempt history• Description of intervention and control conditions• Outcomes assessed, including all measures of tobacco use re-
duction and quitting, and all measures of exposure to tobacco
and measures of potential harm• The definition of 'harm reduction', and quitting• Adverse events (where the intervention included the use of a
pharmaceutical, nicotine- or tobacco-based substitute for to-
bacco smoking)
One author then entered the data into Review Manager 5 software
for analysis, and another checked them.
Assessment of risk of bias in included studies
Two authors (from AF, JHB, NLH, RB for this update; TL & previous
author LS for previous versions) independently assessed the risk of
bias for each included study, following the approach recommended
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We used domain-based evaluation to address the
following areas: random sequence generation; allocation conceal-
ment; blinding (of participants, providers and assessors); and in-
complete outcome data. We assigned a grade (low, high, or unclear)
for risk of bias for each domain, resolving disagreements by discus-
sion with a third author where necessary.
Measures of treatment e4ect
For outcomes measured using continuous variables, for example
carbon monoxide (CO) levels, the preferred outcome was the differ-
ence between the average change from baseline in the intervention
and control groups.
For dichotomous outcomes, we summarized results of each study
as a risk ratio (RR), with a 95% confidence interval (CI).
Dealing with missing data
We assessed the potential for bias due to loss to follow-up. Where
outcomes for individuals were missing, we planned to include them
and assume that they had not stopped smoking or had not changed
their behaviour in a favourable direction. This conservative ap-
proach is standard for the Cochrane Tobacco Addiction Group. We
planned to note any exceptions to this, and to consider the sensi-
tivity of results to different assumptions about missing data.
Assessment of heterogeneity
We assessed whether trials used comparable interventions and
measured similar outcomes, to guide our decision whether to pool
data. Where we did decide to pool data we assessed statistical het-
erogeneity using the I2 statistic (Higgins 2003). We would deem a
value greater than 50% as evidence of substantial heterogeneity.
Assessment of reporting biases
We intended to assess reporting bias using funnel plots; however,
this is only a robust approach where 10 or more RCTs contribute
to an outcome. There are currently too few studies to support this
approach.
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Data synthesis
We planned to pool data for meta-analysis where appropriate, i.e.
where we did not detect substantial clinical and methodological
heterogeneity. For example, we did not intend to pool harm re-
duction interventions using different classes of pharmacotherapy
(such as NRT, bupropion, varenicline). Where data was pooled the
decision whether to use random or fixed-effect models was part-
ly informed by the statistical heterogeneity detected, with an I2 of
50% or over classed as substantial. Ultimately, we pooled studies
using a Mantel-Haenszel fixed-effect model. We considered pooling
behavioural interventions if they were of comparable intensity in
terms of the presence or absence of face-to-face contact, and the
number of contacts.
Subgroup analysis and investigation of heterogeneity
In the event of heterogeneity, we considered subgroup analyses
based on the intervention type (in both the experimental and con-
trol groups) and the characteristics of participants.
Sensitivity analysis
We considered assessment of the sensitivity of meta-analysis re-
sults to the exclusion of studies that we rated as being at high risk
of bias.
'Summary of findings' table
Our aim was to create a 'Summary of findings' table for the primary
outcome of long-term change in health status. However, there were
no studies which reported this outcome. As the only other outcome
measured that we know to have a positive impact on health is com-
plete abstinence, we created a table to summarize the smoking ab-
stinence outcomes for the primary comparisons of each interven-
tion. Following standard Cochrane methodology, we used the five
GRADE considerations (study limitations, consistency of effect, im-
precision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome, and to draw conclusions
about the quality of evidence within the text of the review.
R E S U L T S
Description of studies
Results of the search
Full details of search results are not available for the previous ver-
sions of this review; however, the search we carried out for this up-
date identified 659 non-duplicate records. We assessed the titles
and abstracts of all of these studies and acquired the full text of
60 (representing 48 studies) to conduct a further eligibility assess-
ment. We found nine studies to be eligible after this stage, of which
three were ongoing (Caponetto 2014; NCT02124187; Taskila 2012;
see Characteristics of ongoing studies table for more details). We
therefore performed full data extraction on six completed studies,
and have added them to the review for this update (Benowitz 2012;
Caponnetto 2013; Chan 2011; Hughes 2011; Joksić 2011; Nackaerts
2009), giving a total of 24 included studies.
Included studies
We include 24 studies, which aimed to test interventions to reduce
the harm caused by continued tobacco smoking. Across studies,
this involved behaviour change to reduce tobacco consumption or
to replace traditional tobacco use with alternative products of (po-
tentially) lower risk, or both. Studies typically recruited between
100 and 200 participants in each intervention or control group. The
smallest had 93 participants in total (Riley 2002).
Participants
The methods of recruitment were varied. Most studies relied on
advertising to attract community volunteers. One study proactive-
ly recruited participants by telephoning households and identify-
ing people who smoked (Carpenter 2004). One study used multiple
approaches, including direct mail to households (Etter 2004). One
small study (Hanson 2008) was in adolescents in particular, and an-
other specifically recruited electively hospitalized patients from a
variety of wards in academic hospitals (Nackaerts 2009).Most stud-
ies excluded people currently interested in quitting smoking, but
the assessments and cut-oH points used to establish eligibility var-
ied. Participants generally had to lack current interest in quitting,
but some studies (e.g. Batra 2005; Bolliger 2000; Haustein 2003;
Joseph 2008) also required past failure in a serious quit attempt.
This criterion was intended to exclude people likely to quit easi-
ly without assistance. Exceptions were Kralikova 2009, where par-
ticipants were recruited on the basis that they did not have to be
motivated to quit (cessation was recommended but not manda-
tory), and Joksić 2011, where participants did have to be motivat-
ed to quit smoking but the intervention was smokeless tobacco
and therefore participants were not willing to quit tobacco com-
pletely. However, despite using criteria to exclude people willing
to attempt immediate quitting in the main, the long-term moti-
vation to stop smoking often appeared high. For example, Wen-
nike 2003 reported participants as having an average motivation
to quit of 6.6 on a visual analogue scale of 0 to 10. Little informa-
tion was available on the participants in two of the studies (Aus-
tralia NNCG-017; Nackaerts 2009). Participants in the studies of
PREPs (excluding smokeless tobacco) were volunteers who were
paid for participation in research studies (Benowitz 2012; Mendes
2008; Roethig 2008; Sarkar 2008). In most studies participants had a
baseline average smoking rate of between 20 and 30 CPD; however,
participants had a baseline rate of 12 CPD in Hanson 2008, 19 CPD
in Hughes 2011, and 18 CPD in Sarkar 2008.
Interventions and controls
Nicotine replacement therapy
Fourteen included trials provided or offered nicotine replacement
therapy (NRT). They took place in the USA (Carpenter 2003; Carpen-
ter 2004; Hanson 2008; Joseph 2008; Rennard 2006); Australia (Aus-
tralia NNCG-017); Germany and/or Switzerland (Batra 2005; Bol-
liger 2000; Etter 2004; Haustein 2003); the Czech Republic (Kraliko-
va 2009); Denmark (Wennike 2003); Belgium (Nackaerts 2009); and
China (Chan 2011).
Nine of these trials provided behavioural support to encourage
smoking reduction, and randomized participants to NRT or placebo
(Australia NNCG-017; Batra 2005; Bolliger 2000; Etter 2004; Hanson
2008; Haustein 2003; Kralikova 2009; Rennard 2006; Wennike 2003),
including one (Etter 2004) which also had a control group receiving
only minimal behavioural support. Etter 2004 and Kralikova 2009
offered participants a choice of products, and in one of these partic-
ipants could use a combination of types (Etter 2004). Bolliger 2000
and Rennard 2006 used an inhaler alone; Australia NNCG-017 and
Wennike 2003 provided 2 mg or 4 mg gum, depending on baseline
dependence, while Batra 2005 and Haustein 2003 used 4 mg gum
only. Haustein 2003 involved additional stratification to arms, sup-
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porting reduction for a maximum of either four weeks or six months
(resulting in a 2x2 study design). In the short-term reduction arms
participants were asked at baseline to quit at week four, while in the
long-term arm participants were asked simply to reduce as much as
possible over six months. At the end of the six months, participants
were advised that it was preferable to quit altogether; however, this
was not the original goal and a specific cessation intervention was
not offered. For the purposes of this review we are solely interest-
ed in the two long-term reduction arms (comparing nicotine gum
to placebo gum). Hanson 2008 was borderline for inclusion, and so
not included in meta-analyses. This was because after a short peri-
od of reduction (four weeks) participants were offered a cessation
intervention where they set a quit date and were provided with NRT.
There were two intervention arms: one used nicotine gum and the
other used nicotine patch; however, these were only provided in
the second phase of the study, if participants decided to set a quit
day after the period of reduction.
One study (Nackaerts 2009) investigated the use of nicotine patch-
es versus placebo patches as a substitute for smoking, to induce
"temporary abstinence", during hospitalization.
A further two studies (Chan 2011; Joseph 2008) provided repeated
counselling and encouragement to use NRT, compared to a control
group that received only brief advice on the importance of quitting.
Chan 2011 further split their counselling + NRT group, so that one
group also received add-on counselling to encourage adherence to
the NRT. However, for the purposes of our analysis we combined the
two counselling + NRT groups and compared them to the brief-ad-
vice control. Joseph 2008 provided participants with nicotine gum,
or, if this did not suppress withdrawal, with nicotine patch.
Two other NRT studies did not have a placebo control and were
borderline for inclusion. As a result we have not included them in
our meta-analyses. In Carpenter 2003 participants were recruited
on the basis that they were not interested in quitting immediately,
but that they were interested in quitting within the next six months.
This was a pilot study, assessing whether assistance with cutting
down increased the impact of subsequent brief advice to quit com-
pletely. Intervention participants were given a choice of NRT prod-
ucts and a target of reducing their daily cigarette consumption by
at least 50% in four weeks, after which they were advised to quit,
and given self-help materials to do so if desired. The control group
received brief advice to quit at the initial visit, and those who set
a quit date were offered NRT but no further support. In Carpenter
2004 the initial intervention focused on reduction, but participants
were advised to quit and those that set a quit date were provided
with additional support (i.e. a cessation intervention). Carpenter
2004 had three arms: a no-intervention control, motivational inter-
viewing intended to increase interest in quitting, and advice to re-
duce with an offer of NRT. Both intervention arms included eligibil-
ity for free NRT if a quit date was set. Both Carpenter 2003 and Car-
penter 2004 provided participants with a choice of NRT products
(gum, patch or inhaler; and gum or patch respectively).
Across all NRT studies, the maximum length of time NRT could be
used to aid reduction ranged from nine months (Haustein 2003) to
18 months (Bolliger 2000). In Nackaerts 2009 the nicotine patch was
used as a complete substitute for smoking rather than whilst reduc-
ing. Participants were provided with patches until they were dis-
charged from hospital, for a maximum of seven days.
Bupropion
One USA study (Hatsukami 2004a) offered bupropion or placebo
for 26 weeks to people attempting to reduce their smoking, with
a target of 50% reduction in cigarettes smoked a day. Final fol-
low-up was six months after the end of treatment. Participants who
indicated a willingness to quit at any time remained on assigned
treatment but enrolled in a seven-week cessation programme with
weekly counselling visits followed by 19 weeks of follow-up.
Varenicline
Hughes 2011, carried out in the USA, randomized participants to
either varenicline or placebo for two to eight weeks. Participants
were also provided with four counselling sessions (baseline, two
weeks, four weeks and eight weeks) on methods that could be
used to reduce the amount of cigarettes smoked. The aim of the
study was to see whether varenicline would induce quit attempts
in smokers who were not currently planning to quit. Final follow-up
was six months after baseline.
Electronic cigarettes
Another single study (Caponnetto 2013) encouraged participants
who did not intend to quit to reduce their cigarette-smoking using
electronic cigarettes (ecigs). There were three arms, all of which
were instructed to use an ecig ab libitum; the difference between
the three study arms was the nicotine content of the ecig nicotine
cartridges provided (7.2 mg; 5.4 mg; 0 mg). Participants received 12
weeks-worth of cartridges. The identical appearance of the ecigs
and cartridges was intended to blind participants and investigators
to their treatment allocation. The study took place in Italy, at the
Universita di Catania, and had a follow-up of one year.
Snus
Joksić 2011, which took place in Serbia, used the smokeless tobac-
co product, snus, to encourage participants to reduce their smok-
ing. Although participants were told that their ultimate goal should
be to quit, the aim in the first 24 weeks was solely cigarette reduc-
tion. We included this study despite the goal to quit cigarettes, as it
instructed participants to switch to snus, and therefore not to quit
tobacco completely. Participants were told to use a sachet of snus
every time they felt the urge to smoke. The control group received
placebo sachets of smokeless tobacco, which were almost identi-
cal to the snus product in appearance, feel, pH and taste, but con-
tained no nicotine or tobacco. Study follow-up took place up to two
years post-baseline. Joksić 2011 was sponsored by Swedish Match.
Other PREPs (excluding smokeless tobacco)
There were also four studies comparing PREPs (excluding smoke-
less tobacco) to conventional cigarette use (Benowitz 2012;
Mendes 2008; Roethig 2008; Sarkar 2008). For the purposes of this
review we present studies of smokeless tobacco separately from
these other PREPs, which were all products mimicking cigarette
smoking whilst potentially reducing the intake of harmful compo-
nents. Three of the PREP studies were funded by a tobacco com-
pany (Mendes 2008; Roethig 2008; Sarkar 2008), and the fourth
was funded by the National Cancer Institute and National Insti-
tute on Drug Abuse, National Institutes of Health, but a tobac-
co company provided the research cigarettes (Benowitz 2012). All
four studies investigated products designed to reduce the risks of
smoking in different ways. Mendes 2008 evaluated light and ul-
tra-light tar cigarettes compared to continued use of convention-
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al cigarettes; Sarkar 2008 investigated carbon-filtered cigarettes;
Benowitz 2012 investigated reduced-nicotine content cigarettes,
and Roethig 2008 evaluated an electrically-heated cigarette smok-
ing system (EHCSS), a device used to smoke regular cigarettes,
rather than an ecig. These studies had six- to 12-month follow-up,
including regular research clinic visits for collection of samples for
biochemical assessment of levels of markers of exposure and risk.
Behavioural interventions
Two studies investigated behavioural interventions to change
smoking behaviour without the use of pharmaceutical aids, nico-
tine or tobacco substitutes for cigarettes. Riley 2002, involving
community volunteers only interested in reduction, compared two
guided methods to reduce the number of cigarettes smoked. One
intervention used computerized scheduled smoking to achieve a
gradual reduction to 50% of baseline in two weeks. The comparison
condition provided a treatment guide instructing in gradual reduc-
tion by selectively eliminating cigarettes. Glasgow 2009 provided
an intervention for members of a Health Maintenance Organization
who were due to have outpatient surgery or a diagnostic procedure
via telephone. The individualized counselling consisted of partici-
pants being advised to gradually reduce their cigarette smoking by
50% or more, with cessation encouraged following reduction. This
intervention was compared to usual care in the form of usual care
plus generic health mailings.
Outcomes
The main outcomes in most of the included studies were reduc-
tion or cessation, and these all had follow-up of at least six months.
However, three of the studies investigating PREPs measured nei-
ther reduction nor cessation, and instead used biochemical assess-
ments to measure potential markers of health risk. The smoking
reduction and cessation outcomes used in this review were all as-
sessed at least one month after the end of the treatment period, as
well as being at least six months after the start of the intervention.
The most consistently used reduction outcome was a reduction in
self-reported cigarettes a day of more than 50% from baseline. Most
studies used sustained reduction at multiple follow-ups, validated
by any level of reduction in baseline CO. Other reduction measures
reported in some studies were average reduction in CPD, and aver-
age reduction in CO levels, cotinine levels and thiocyanate levels.
These reductions could be expressed as absolute or percentage re-
ductions, and were typically calculated using available data with-
out imputing values for dropouts, and included people who were
no longer smoking at assessment.
In those studies that did investigate health outcomes, analyses of
changes in biomarker levels amongst reducers did not always dis-
tinguish between treatment groups. In addition, the wide variation
in the markers used and the ways these were assessed meant that
we could not attempt meta-analysis for these outcomes.
Ongoing studies
During the 2016 update we also identified three studies deemed to
be ongoing (Caponetto 2014; NCT02124187; Taskila 2012), where
results are not currently available. These may be eligible for inclu-
sion in a subsequent update. Caponetto 2014 is another ecig study
which recruited people with schizophrenia with no intention of
quitting. It has three trial arms: 1) high-nicotine ecig (24 mg); 2) ecig
with no nicotine; and 3) nicotine-free inhalator. NCT02124187 is a
very similar ecig study with the same investigator, recruiting partic-
ipants with major depressive disorder, with the same study arms.
Both of these studies began in 2014 and have a planned 52-week
follow-up. Taskila 2012 is a completed but currently unpublished
study assessing the effectiveness of pharmacist-delivered behav-
ioural reduction programmes. Planned length of follow-up was six
months. For further detail see Characteristics of ongoing studies.
Excluded studies
We found a variety of other studies which were potentially relevant
but did not meet our inclusion criteria because they recruited par-
ticipants that wanted to quit as a short-term aim, or the aim of the
study was to quit smoking rather than to simply to reduce smok-
ing or harm. Another common reason for exclusion was that the
long-term change in smoking behaviour and associated change in
biomarkers of harm were not a target of the study. Many of these
were very short-term within-subject cross-over studies of smokers
switching to PREPs developed by the tobacco industry. Another
short-term excluded study used payment for reduced levels of car-
bon monoxide to encourage smoking reduction (Lamb 2005). One
study estimated the amount of compensatory smoking in people
switching to lower-tar cigarette brands (Frost 1995). For more de-
tail on excluded studies and the reasons for exclusion, see Exclud-
ed studies.
Risk of bias in included studies
See Characteristics of included studies and Figure 1.
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Figure 1.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 1.   (Continued)
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Allocation
We judged 15 of the included studies to be at unclear risk of bias for
random sequence generation. This was simply because the studies
stated that they were randomized but then did not specify how the
randomization sequence was generated, making it impossible to
judge whether or not this was done adequately. We judged all other
studies to be at low risk of bias for sequence generation, as they re-
ported being randomized with a robust method of sequence gener-
ation (Bolliger 2000; Caponnetto 2013; Chan 2011; Etter 2004; Glas-
gow 2009; Hatsukami 2004a; Haustein 2003; Joksić 2011; Joseph
2008).
When assessing allocation concealment, we rated most trials at un-
clear risk, due to a lack of reporting, i.e. 18 studies did not speci-
fy how participant allocation to study groups was concealed prior
to and during randomization. However, we judged the remaining
seven studies to be at low risk, as treatment was either organized
and/or distributed by an independent pharmacist or researcher
with no further involvement in the study (Bolliger 2000; Caponnet-
to 2013; Hughes 2011; Joksić 2011), or allocations were concealed
up to treatment delivery in opaque sealed envelopes (Chan 2011;
Haustein 2003; Joksić 2011).
Blinding
In seven cases we deemed blinding to be insufficient and rated the
studies at high risk (Benowitz 2012; Carpenter 2004; Joseph 2008;
Mendes 2008; Riley 2002; Roethig 2008; Sarkar 2008). Carpenter
2004 tested a behavioural intervention, which would be impossi-
ble to blind. Potential bias would have been minimized if the study
arms had received the same level of support and if outcomes were
biochemically verified, but this was not the case. In the other stud-
ies rated as high risk, group allocation was not blinded and the
products provided across groups differed in nature so that there
was a risk of performance bias. For example, in Joseph 2008 there
were differences between the arms in the counselling provided,
and in whether NRT was supplied. In nine cases we judged blind-
ing to be at an unclear risk of bias (Australia NNCG-017; Batra 2005;
Caponnetto 2013; Hanson 2008; Hatsukami 2004a; Kralikova 2009;
Nackaerts 2009; Rennard 2006; Wennike 2003). This was because
the study was described as "blinded", "double-blinded", or used a
placebo, but with no details given as to who was blinded or how
this was achieved, or both.
Incomplete outcome data
Loss to follow-up was high in some trials. Although this is also a
problem in cessation trials where participants wish to quit, study
reports indicate that it was a larger problem in this population
of smokers who were not as motivated to change their smoking
behaviour. We rated three studies (Benowitz 2012; Mendes 2008;
Sarkar 2008) at high risk of bias for this domain, as there was a sub-
stantial difference in dropout rates between study groups.
Outcomes derived from continuous variables (mainly markers of
health outcomes) were generally reported for continuing partici-
pants only. If dropouts are less likely to have changed their behav-
iour, these outcomes will overestimate the change in the trial pop-
ulation. In using a dichotomous outcome for reduction in cigarettes
and calculating rates on an intention-to-treat basis, we, like the
trialists, made the assumption that dropouts had not reduced by
more than 50%. This will underestimate the change in the popula-
tion if our assumption is incorrect. It does not remove the potential
to introduce bias if the true change in behaviour amongst dropouts
is confounded by treatment group. The trials of PREPs had particu-
larly high losses to follow-up, which was higher in groups using the
unfamiliar products.
Other potential sources of bias
Studies typically reported sustained reduction measured by a self-
reported cigarette consumption of less than 50% of baseline, vali-
dated by reduced levels of CO at follow-up visits. However, Hanson
2008, Hughes 2011 and Nackaerts 2009 did not report full informa-
tion on smoking reduction in the long term. Hanson 2008 did not re-
port reduction or cessation rates to the full length of follow-up (six
months), or split by arm. Hughes 2011 covered self-reported smok-
ing reduction at two-month follow-up and then CO-validated absti-
nence at six months, and Nackaerts 2009 gave self-reported absti-
nence at six months. Etter 2004, a study in the NRT group, did not re-
port sustained abstinence at the longest (two-year) follow-up, and
did not use biochemical validation because there was no personal
contact with participants. Since these factors could overestimate
the true reduction we tested the sensitivity of the relevant meta-
analysis to exclusion of this trial.
Three of the included studies remain unpublished; two were pre-
sented at conferences (Haustein 2003; Nackaerts 2009) and one
was identified from internal reports provided by Pfizer (Australia
NNCG-017).
E4ects of interventions
See: Summary of findings for the main comparison Interventions
to reduce the harms caused by smoking in people who cannot or
do not want to quit smoking
Type of intervention
Nicotine replacement therapy
Smoking reduction outcomes
We pooled eight trials of nicotine replacement therapy (NRT) versus
placebo in adults. Overall there was a statistically significant effect
of NRT on the likelihood of reducing cigarette use by 50% or more
from baseline (risk ratio (RR) 1.75, 95% confidence interval (CI) 1.44
to 2.13; 3081 participants; Analysis 1.1; Figure 2). There was mod-
erate heterogeneity (I2 = 45%). Two studies, Etter 2004; Kralikova
2009, contributed most weight to the analysis. Etter 2004 used self-
reported reduction and many more participants claimed to have
reduced than in other studies, although the relative effect of treat-
ment was smaller. We used data from the two-year follow-up in the
analyses but also tested the sensitivity to the use of five-year fol-
low-up data. Kralikova 2009 was not typical because participants
appear to have been more motivated to quit than to reduce, and
many did so. We conducted a sensitivity analysis to assess the im-
pact of excluding these two studies. Since they showed relatively
less effect on reduction, the effect was to increase the point esti-
mate whilst widening the confidence intervals and reducing het-
erogeneity. However, the effect was still statistically significant (RR
2.77, 95% CI 1.88 to 4.08, I2 = 9%; 2233 participants). Etter 2004 al-
so had a non-placebo control group, not included in the analyses
above. Including this group in the control condition would have in-
creased the effect. Using the five-year data for this study did not
substantially alter the result.
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Figure 2.   Forest plot of comparison: 1 Nicotine replacement therapy to assist smoking reduction versus placebo,
outcome: 1.1 Reduction in cigarettes/day of > 50% of baseline or cessation.
 
We performed a subgroup analysis to see whether the effect dif-
fered according to the type of NRT being used (i.e. a choice of NRT,
nicotine gum, or nicotine inhaler; Figure 2), and found that NRT re-
sulted in significantly more reducers than placebo in all cases. How-
ever, there is evidence of between-group differences (P = 0.009)
with nicotine gum (RR 2.50, 95% CI 1.57 to 4.00, I2 = 34%; 1404 par-
ticipants; Analysis 1.1.2) and nicotine inhaler (RR 3.39, 95% CI 1.70
to 6.77, I2 = 0%; 829 participants; Analysis 1.1.3), resulting in more
reducers than choice of NRT (RR 1.40, 95% CI 1.11 to 1.75, I2 = 0%;
848 participants; Analysis 1.1.3) relative to placebo.
Joseph 2008 and Chan 2011 differed from the other studies in com-
bining NRT and counselling versus a brief advice control, so we
pooled these trials separately (RR 1.75, 95% CI 1.26 to 2.43, I2 = 32%;
1306 participants; Analysis 2.1). Again, there was a statistically sig-
nificant effect on reduction; however, Chan 2011 was a larger study
and therefore contributed much of the weight. Joseph 2008 as a
single study found a small non-significant effect.
Cessation outcomes
Pooling the eight NRT-versus-placebo trials in adults, we found a
statistically significant effect of NRT in increasing quit rates by the
end of follow-up (RR 1.87, 95% CI 1.43 to 2.44; 3081 participants;
Analysis 1.2) with moderate heterogeneity (I2 = 30%). We again pro-
duced a subgroup analysis to assess any effect of the type of NRT
used. No significant differences emerged between subgroups. For
all three subgroups NRT resulted in statistically significantly higher
pooled quit rates than placebo (Analysis 1.2.2; Figure 3).
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Figure 3.   Forest plot of comparison: 1 Nicotine replacement therapy to assist smoking reduction versus placebo,
outcome: 1.2 Cessation at long-term follow-up (subgroups by type of NRT).
 
Pooling the two studies which compared NRT with behavioural
support to brief advice found no statistically significant effect (RR
1.49, 95% CI 0.89 to 2.50, I2 = 27%; 1306 participants; Analysis 2.2),
with neither study individually finding a significant effect on quit
rates (Chan 2011; Joseph 2008).
Nackaerts 2009 was the only study in the review which investigat-
ed the use of NRT (specifically nicotine patches) to aid temporary
abstinence. This study only reports abstinence at long-term (six-
month) follow-up and found almost identical quit rates in the patch
(44/150; 29%) and placebo (41/146; 28%) groups.
In two studies the control groups did not get a placebo and there
was the option of a cessation intervention at the end of the short-
term reduction intervention (as previously discussed, these studies
were borderline included and therefore not pooled in meta-analy-
ses). In the first (Carpenter 2003), cessation rates were non-signifi-
cantly different (5/32 versus 3/35, RR 1.82, 95% CI 0.47 to 7.02) and
non-quitters reduced their CPD compared to controls. In the sec-
ond (Carpenter 2004), reduction and quit rates were significantly
higher in the NRT and behavioural support group than in the no-
treatment control, but advice to reduce before quitting had sim-
ilar effects on reduction and cessation to the motivational inter-
viewing intervention designed to increase interest in quitting. We
did not pool one small pilot study amongst adolescents (Hanson
2008), which also gave the option of a cessation intervention after a
four-week reduction intervention. Furthermore, cessation was not
reported by group and a reduction of more than 50% was not re-
ported at six-month+ follow-up. There was no evidence of any treat-
ment effects, and although average CPD was smaller in all three
conditions at six months, average CO and cotinine levels were non-
significantly higher than at baseline.
Adverse events (AEs)
Nine of the fourteen NRT studies compared one arm receiving NRT
to another arm receiving placebo or no NRT, and reported on ad-
verse events (Batra 2005; Bolliger 2000; Carpenter 2004; Etter 2004;
Haustein 2003; Joseph 2008; Kralikova 2009; Rennard 2006; Wen-
nike 2003). The reporting across studies was generally sparse and
varied. There was some evidence of a small elevation in non-serious
adverse events in the study arms receiving active treatment; for ex-
ample, Haustein 2003 found that nausea and vomiting were more
common in the active (59/193) than in the placebo group (17/192);
Kralikova 2009 found that 82 adverse events occurred in the active
arm versus 26 in the placebo arm (N = 209 and 105 respectively);
and Batra 2005 reported 506 AEs in the active group and 370 in the
control group (N = 184 and 180 respectively). However, this is also
true for NRT used for cessation (Stead 2012), and there were no re-
ports of any serious adverse events that might have been attributed
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to NRT use alongside continued smoking in any of the studies re-
porting safety outcomes.
Other markers of cigarette consumption
We summarize reported changes in CPD, CO, thiocyanate and co-
tinine, expressed as percentage or absolute differences from base-
line values, for the studies for which data were available in Analysis
1.3 (NRT versus placebo) and Analysis 2.3 (NRT + counselling versus
brief advice). Studies typically showed reductions from baseline in
both treatment and control groups, but this was usually based on
continuing participants only. Differences between groups where re-
ported were not always statistically significant. Because of the mul-
tiple differences in the ways in which changes were calculated and
reported, we did not attempt any formal meta-analysis.
People who reduce their cigarette consumption may inadvertently
compensate for the reduction in nicotine by smoking the remain-
ing cigarettes more 'efficiently' and therefore do not reduce their
intake of toxins as much as might be suggested from CPD. Using
NRT to assist reduction may help avoid this compensation, so that
toxin levels are reduced more for a similar level of CPD reduction.
We found relatively little data about either compensation gener-
ally amongst reducers, or differential levels of compensation for
NRT and placebo users. Bolliger 2000 reported that at 24 months
sustained reducers had an average CPD of 25% of baseline, whilst
CO and cotinine levels were only about 50% of baseline. The same
study presented data on cigarette and CO reduction in the sub-
group of intervention and placebo participants who were still us-
ing inhalers daily at various points during the treatment phase. Af-
ter 18 months, the 22 active inhaler-users had an average reduc-
tion in CPD of 64% of baseline with a range of 0% to 100%. CO lev-
els were only reduced by an average of 29% of baseline. Changes
in CO levels ranged from a decrease of 92% to an increase of 222%.
The eight placebo-users had a significantly smaller (P = 0.02) per-
centage reduction in CPD than the active inhaler-users (reduced to
33% of baseline, range 20% to 100%) and a non-significantly small-
er percentage reduction in CO (reduced to 82% of baseline, range
50% to 177%). Batra 2005 reported the proportion of participants
with a sustained reduction in CO levels of over 20% from baseline
at 13-month follow-up. The proportions achieving this (13.6% ac-
tive versus 5.6% placebo) were higher in both conditions than the
proportion reporting sustained reduction greater than 50% in CPD,
suggesting that all the reducers had achieved at least a 20% reduc-
tion in CO.
Health markers
Six studies (Batra 2005; Bolliger 2000; Haustein 2003; Joseph 2008;
Kralikova 2009; Rennard 2006) assessed some biomarkers of dis-
ease risk, and we report these narratively in Analysis 1.4. Changes
from baseline were assessed in those with available data and typ-
ically showed improvements over time but not between groups.
Bolliger 2000 and Haustein 2003 assessed differences between
those participants who successfully reduced and those who did
not, rather than between randomized groups. Again, there were not
consistent between-group differences. One study (Rennard 2006)
found no differences across treatment groups in any markers of car-
diovascular risk, but also reported changes in cardiovascular risk
factors from baseline to four-month follow-up in individuals who
had reduced by more than 50%, including quitters. Results were not
reported by treatment group, and we cannot separate the benefit
of quitting from that of reducing; there was a significant increase
in high-density lipoprotein (HDL) cholesterol. It was not possible
to meta-analyse any of the reported data due to variations in the
markers measured, the ways these were measured and the com-
parison groups used.
Bupropion
Hatsukami 2004a, the single study testing bupropion, did not de-
tect a long-term effect on reduction or cessation. Participants who
became willing to make a quit attempt entered a cessation pro-
gramme. When using all randomized participants as the denomi-
nator, long-term cessation rates were not statistically significant-
ly different between the bupropion and placebo groups (RR 1.27,
95% CI 0.67 to 2.40; 594 participants; Analysis 4.1.1), although those
in the bupropion group made their quit attempts sooner and had
better short-term quit rates. Smoking reduction in participants who
never attempted to quit, as defined by a reduction in urinary coti-
nine of more than 50%, was greater during the treatment phase but
did not differ significantly at 12-month follow-up (RR 1.01, 95% CI
0.62 to 1.67; 594 participants; Analysis 4.1.2). Reduction in cotinine
more than 50%: 2% (3/153) bupropion versus 5% (8/174) placebo,
not statistically significant (P = 0.17) excludes participants who en-
tered the cessation arm of the study. The between-group difference
in cotinine measured continuously was also non-significant at 12-
month follow-up (Analysis 4.2).
Health markers were not assessed in this study.
Eight participants in the bupropion group and three in the placebo
group reported adverse events that met study criteria for serious
events. One of these was thought to be related to the bupropion
treatment.
Varenicline
Hughes 2011 assessed point prevalence CO-verified quit rates at
six-month follow-up, and found that 14% of the varenicline group
and 7% of the placebo group were abstinent; however, this differ-
ence was not statistically significant (RR 1.95, 95% CI 0.86 to 4.40;
218 participants; Analysis 5.1). Smoking reduction was only report-
ed at two-month follow-up, with statistically significant differences
in self-reported CPD and exhaled CO.
Health markers were not assessed at all in this study.
There was no significant difference in adverse events between
groups, with 12% of the active group and 10% of the placebo group
stopping their medication due to an AE.
Electronic cigarettes
Caponnetto 2013 was the only completed study investigating ecigs
as a harm reduction aid at the time of the searches. The study com-
pared nicotine and non-nicotine ecigs, and found that there was
a reduction in the number of regular cigarettes smoked, but with-
out statistically significant between-group differences. The RR for
more than a 50% reduction at one-year follow-up was 1.28 (95%
CI 0.76 to 2.17; 300 participants; Analysis 6.1.1), and for abstinence
2.75 (95% CI 0.97 to 7.76; 300 participants; Analysis 6.1.2); both were
statistically non-significantly in favour of ecigs with nicotine car-
tridges. The CPD reduction finding was mirrored by non-significant
between-group differences in CO at 12-month follow-up (Analysis
6.2).
Caponnetto 2013 also assessed whether weight, resting heart rate,
systolic blood pressure (SBP) or diastolic blood pressure (DBP)
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changed over time or between groups. There were no significant
differences for any of these outcomes (Analysis 6.3). The frequency
of adverse events was reported to be comparable across groups at
each of the three assessment time points during the study (base-
line, week 12, week 52). All symptoms were significantly reduced
between baseline and week 52 in all groups (P < 0.001). In particu-
lar, the rates of shortness of breath were reduced from 20% to 4%
two weeks into the study. No serious adverse events were reported
during the study.
Snus
The one study (Joksić 2011) that investigated replacing cigarette
smoking with another form of tobacco (smokeless, snus) found that
there was not a significant difference in the number who achieved
more than a 50% cigarette reduction (RR 0.94, 95% CI 0.81 to 1.11;
319 participants; Analysis 7.1.1) and complete abstinence (RR 3.06,
95% CI 0.84 to 11.08; 319 participants; Analysis 7.1.2) between the
active and placebo groups at six months. However, statistically sig-
nificantly more participants in the snus group achieved more than
a 75% reduction at six-month follow-up (15/158, 9.5% in the snus
group and 4/161, 2.5% in the placebo group; P = 0.01). It should
be noted that the last of these analyses was the result of an ex-
ploratory, post hoc investigation. Although this study went on to
48-month follow-up, we only use the data up to 24 months here,
as after this point anyone who had not reduced by more than 50%
or quit was excluded. When we assessed markers of consumption
(CPD, CO and cotinine) as continuous measures, there were no sig-
nificant between-group differences at 48 weeks; however, in both
groups CPD and cotinine reduced by approximately a third, and CO
reduced by around half (Analysis 7.2).
A number of health markers were measured; however, in no case
did we find any differences over time or between groups (Analysis
7.3). Only two adverse events were reported in the snus arm of the
study, and neither was judged to be associated with the use of snus.
Other PREPs (excluding smokeless tobacco)
We summarize the main findings of these four studies narrative-
ly. All reported data on multiple biomarkers at multiple follow-up
points (Analysis 8.1). Difficulties in interpreting the results include
the large variation between participants, and the loss to follow-up
of participants who did not maintain use of the test products. Some
measures showed marked changes from baseline to the end of fol-
low-up; for example, CPD typically increased in both experimental
and control groups. Switching from full-strength (F) to low- (L) or
very low-tar (UL) cigarettes (Mendes 2008) led to significantly low-
er average nicotine levels in the UL than in the F groups. CPD in-
creased in all groups, possibly because cigarettes were provided
free in a residential clinic. Carboxyhaemaglobin (COHb) levels were
similar between the F and UL groups, but higher in the L groups.
Overall, although some exposures were reduced in the heavy smok-
ers who switched to lower-tar alternatives, the absolute differ-
ences were not large, even when statistically significant. Use of
carbon-filtered low- and medium-tar cigarettes led to reduced lev-
els of gas phase biomarkers, but had no impact on particulate
phase biomarkers (Sarkar 2008). Using an electrically-heated ciga-
rette smoking system (EHCSS) reduced exposure to tobacco smoke
constituents, especially carboxyhaemoglobin. Nicotine levels were
reduced, which, combined with the higher dropout in the EHCSS
group, suggests that the device may not have been very acceptable
to smokers (Roethig 2008). In this study markers or cardiovascular
risk factors including white blood cell counts and levels of HDL and
LDL did show significant change in favourable directions compared
to conventional cigarette use. Benowitz 2012 conducted bi-week-
ly clinics in a community clinic setting, a slightly different context
to the aforementioned studies. This may account for the fact that
cigarette consumption stayed relatively stable in both study condi-
tions (reduced nicotine content-cigarettes versus usual cigarettes).
Markers of consumption, such as CO, and cardiovascular biomark-
ers also stayed approximately the same in both groups. However,
markers of nicotine consumption decreased in the group receiving
reduced nicotine content-cigarettes. It would seem that, although
nicotine consumption was successfully reduced in the experimen-
tal group, this did not result in participants compensating for this
by smoking more cigarettes and thereby increasing their CO con-
sumption.
None of the four studies of PREPs reported reduction as a binary
outcome (with a 50% cut-oH), and only Benowitz 2012 assessed and
reported smoking cessation. Only very small numbers quit (2/80
in the experimental, reduced nicotine cigarettes group, and 1/55
in the control, regular cigarettes group), resulting in a statistically
non-significant effect, with very wide confidence intervals (RR 1.38,
95% CI 0.13 to 14.79; 135 participants; Analysis 8.2).
A summary of measures of health markers across studies of PREPS
can be found in Analysis 8.3.
Behavioural interventions
In a study comparing computerized scheduled reduction to reduc-
tion by selective elimination of cigarettes (Riley 2002), both groups
achieved statistically significant reductions in cigarettes from base-
line, but there was no difference between the groups (RR 0.99, 95%
CI 0.42 to 2.34; 93 participants; Analysis 9.1.1). There were also re-
ductions in CO which did not differ between groups (Analysis 9.2).
Point prevalence quit rates were higher at 12-month follow-up than
at the end of treatment in both groups, suggesting no deterrent ef-
fect on quitting. At 12 months quit rates were statistically non-sig-
nificantly higher in the computer scheduled group than the selec-
tive reduction group (RR 1.86, 95% CI 0.47 to 7.32; 93 participants;
Analysis 9.1.2).
An intervention of repeated telephone counselling and mailings
was not shown to assist reduction after 12 months relative to a
control of health mailings in Glasgow 2009. No indicators of reduc-
tion were significantly higher in the intervention than in the con-
trol group at 12 months (25% vs 18.6% for 50% or more CPD reduc-
tion, 11% versus 7% for abstinence). The proportions reducing CO
by more than 50% were also similar across groups at 12 months
(14.0% versus 14.1%). When we looked at the overall continuous
rates of CPD and CO reduction, both groups had reduced their cig-
arette consumption (by approximately a quarter of their baseline
rate) and CO levels (by approximately a sixth of their baseline rate)
on average (Analysis 10.2).
D I S C U S S I O N
Summary of main results
The studies included in this review assess ways to help people who
smoke to potentially reduce the harm caused by their smoking, ei-
ther by reducing the number of cigarettes they smoke (with the
help of behavioural methods to encourage change, or using phar-
maceutical, nicotine or reduced-risk tobacco products as partial
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substitutes, or both), or by fully substituting regular tobacco prod-
ucts with 'reduced-risk' alternatives.
Studies included tested a wide range of approaches in the form of
harm reduction interventions: nicotine replacement therapy (NRT);
bupropion; varenicline; ecigarettes (ecigs); snus; other potential re-
duced-exposure tobacco products (PREPs); behavioural reduction
advice; and a computerized smoking reduction programme. The
opportunities for meta-analyses were limited, but there is evidence
that NRT has an effect on successful smoking reduction (50%+ re-
duction in cigarettes a day (CPD)) and quit rates. There is insuffi-
cient evidence to suggest whether or not other harm reduction in-
terventions are effective in reducing the harm caused by tobacco.
Included trials suggest that people who use NRT to reduce their
smoking are more likely to be able to reduce their cigarette con-
sumption than people attempting to reduce with placebo. All the
trials included a follow-up period when NRT was no longer provid-
ed, and one trial had follow-up 20 months after the end of NRT pro-
vision. There was no evidence that using NRT, with an aim to as-
sist reduction, diverted people from attempting to quit, since ces-
sation rates were also higher in NRT-treated groups. Whilst the trial
evidence supports the concept of using NRT to reduce the amount
smoked, showing a significant effect and an effect size that would
be clinically important in many treatments, the absolute benefit
from this use of NRT seems to be small. NRT increased the number
of long-term sustained reducers, but against a background of very
little reduction amongst the control group. Treatment typically in-
creased the proportion of successful reducers from 1 - 3% to 6 - 9%,
and the health benefit even for these people is unclear.
Some of the included studies allowed a comparison between
change in CPD and changes in other measure of exposure to tobac-
co smoke. Data on markers of consumption are typically reported
in different ways across studies, which makes it difficult to produce
pooled across-study estimates of changes. However, these studies
confirm that the extent to which participants reduced their CPD
consumption was typically greater than the observed percentage
reduction in other measures of their exposure to tobacco smoke,
such as carbon monoxide (CO) and cotinine (Batra 2005; Joksić
2011 Rennard 2006; Wennike 2003; Glasgow 2009). Another review
has estimated that the reduction in CO is typically about a third less
than the reduction in CPD (Hughes 2005). However, it should be
noted that as the baseline CO reading in a non-smoker is typically
not zero, one would not necessarily expect percentage reductions
in CO and CPD to map directly on to each other, even in the absence
of compensatory smoking.
As predicted, studies provided very little information on changes in
health or markers of this. Where this was reported, between-group
comparisons were generally not made. Where they were made,
there appeared to be no evidence of consistent benefits resulting
from any of the interventions in terms of health and markers of
health. Reporting on adverse effects was limited, but those studies
that did report on them found nothing that has not already been
detected when using the medications tested for their more tradi-
tional indication of cessation. This suggests that there is no addi-
tional risk of using NRT, bupropion, ecigs or varenicline for the pur-
poses of harm reduction.
Overall completeness and applicability of evidence
The field of harm reduction has progressed since the last update
of this review was published in 2007 (partially demonstrated by
the NICE harm reduction guidance published in the interim (NICE
2013). As a result, there is a wider range of interventions aiming for
tobacco harm reduction (for example, ecigs). We took this into ac-
count and expanded our search terms for this update, making the
search less sensitive and allowing us to broaden our reach for rel-
evant studies. As a result we are confident that we have account-
ed for changes in the research field and have found the available,
relevant literature. As expected we identified studies testing inter-
ventions new to this review (e.g. varenicline, snus, ecigs); however,
in most cases we found only one study for each intervention, limit-
ing the power needed to detect an effect, and hence the strength
of the conclusions we can draw, due to imprecision. NRT there-
fore remains the only intervention for which there were multiple
studies and for which we could produce meta-analyses. The lack
of investigation into alternative approaches could account for the
lack of effects observed in reducing smoking and increasing ab-
stinence rates. The effect estimates with their corresponding 95%
confidence intervals for harm reduction interventions other than
NRT overlap with those in our meta-analysis of NRT studies, so it is
plausible that all medications work equally to support reduction,
but further high-quality research would need to test this assump-
tion.
The primary outcome which we wished to test in this review was
long-term health, and it was impossible to do so. This would have
given us a clearer idea of any benefits of harm reduction for those
people who do not achieve cessation. Some studies measured bio-
markers of health risk, but these were typically measured at short-
term follow-up, inconsistently across studies, and only in those
participants who had not dropped out earlier from the study. In
many cases comparisons were only between those who had suc-
cessfully changed their behaviour versus those who had not, rather
than across randomized groups, making it impossible to assess
the effects of the intervention in comparison to the control condi-
tion. However, cessation results in substantial health benefits (An-
thonisen 2005; Doll 2004), so this was still a valuable outcome to
assess.
Quality of the evidence
For a number of 'Risk of bias' domains across studies, we rated the
risks of bias as unclear, due to a lack of reporting. For instance, a
number of trials (particularly those of NRT versus placebo) were de-
scribed as "blinded", but without full details of how this was carried
out, i.e. who was blinded and how it was done. In these cases bias
is probably not a problem, but we cannot be sure. Some studies
provided different harm reduction aids, or administered aids differ-
ently across study groups, meaning the studies were impossible to
blind; we judged them to be at high risk of performance bias. An-
other key concern for research in the field of harm reduction is that
it may motivate those with a stake in the tobacco industry to manu-
facture and test 'reduced-harm' alternatives to tobacco, in order to
provide an alternative to complete cessation. All of the studies test-
ing PREPs (including snus) in this review were in some way linked to
the tobacco industry: Joksić 2011; Mendes 2008; Roethig 2008 and
Sarkar 2008 were all sponsored by the tobacco industry. Benowitz
2012 was not, but the test cigarettes were supplied directly by the
tobacco industry.
We planned to assess the quality of the evidence contributing
to long-term health status outcomes using the GRADE approach
(GRADE 2012). However, this proved impossible, as no studies re-
ported on this outcome. As cessation is the only other outcome that
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we know can be used as an accurate measure of harm reduction, we
have used the GRADE approach to assess the quality of the evidence
contributing to the main comparison for each harm reduction aid
(Summary of findings for the main comparison). In most cases we
rated the evidence as 'low', and in some cases (low-nicotine ciga-
rettes versus regular cigarettes; behavioural reduction advice ver-
sus health mailings) 'very low'. Across all outcomes this was due
to imprecision, i.e. a small number of studies, resulting in a small
number of events and wide confidence intervals around the effect
size. In the case of the low-nicotine cigarettes versus regular ciga-
rettes cessation outcome this was also due to the fact that the study
treatments were unblinded, providing the potential for detection
bias, and that there were differential participant dropout rates be-
tween study groups. In the case of the behavioural reduction ad-
vice versus health mailings cessation outcome we also downgrad-
ed the evidence due to indirectness. The only study investigating
this comparison was conducted in a very specific population (peo-
ple awaiting surgery), and so the findings may not be applicable to
the general population.
Agreements and disagreements with other studies or
reviews
The literature investigating the potential health benefits of inter-
ventions aimed at reducing smoking behaviour is very conflicted,
and no clear conclusions have been drawn (Begh 2015; Hughes
2006; Tverdal 2006), leaving the overall public health benefit un-
certain. Unfortunately, the data on biomarkers of health reviewed
here do not resolve these problems. This is largely due to the design
and reporting of the studies, which could be improved in future re-
search.
An earlier review of the use of PREPs specifically to reduce harm
concluded that "there is no evidence to suggest that there is
enough of a reduction in tobacco toxin exposure with any of the ex-
isting PREPs to expect a significant reduction in disease risk, nor do
we know the extent of toxin exposure reduction that is necessary
to result in reduction of disease" (UMN TTURC 2005). Of particular
note is that some participants using some types of PREPs had high-
er levels of CO than they had when smoking normally (for example,
Fagerström 2000; Fagerström 2002b; Rennard 2002; Strasser 2007).
This may be because smokers overestimate the 'reduced risk' of
PREPs and compensate for this by consciously smoking more, or
because smokers using PREPs are withdrawing from the compo-
nent of the PREP that has been reduced and are increasing their
cigarette consumption to compensate for this.
Aside from the direct health benefits that could be achieved by re-
ducing smoking and the harmful components of cigarettes, harm
reduction interventions could improve public health by ultimate-
ly leading to greater cessation rates in the long term. Limited evi-
dence means this is currently difficult to assess across harm reduc-
tion interventions; however, the pooled group of studies compar-
ing NRT to placebo in adults provides support for this hypothesis.
This may occur because smoking reduction acts as a mediator of
the effect of harm reduction interventions on cessation. Our review
also found that the studies comparing NRT to placebo demonstrat-
ed a positive association between successful reduction and the in-
tervention. Reviews by Hughes 2006 and Asfar 2011, also investi-
gating the association between reduction and quitting, have found
that the two are positively linked. However, in Asfar 2011 (which,
like us, only looked at studies of smokers unwilling or unable to
quit) this was only the case when interventions involved pharma-
cotherapy to aid reduction; the evidence was inconclusive for inter-
ventions offering only behavioural support.
NRT, bupropion, varenicline and behavioural reduce-to-quit inter-
ventions have all been found to be effective cessation interventions
in smokers who would like to quit (Cahill 2016; Hughes 2014; Lind-
son-Hawley 2012; Stead 2012). The evidence for ecigs as a quitting
aid is sparse, but the two randomized controlled trials included in
the Cochrane Review on the subject indicate that they also have a
favourable effect on quitting (Hartmann-Boyce 2016).
A U T H O R S '   C O N C L U S I O N S
Implications for practice• Some people who smoke and do not wish to quit can be helped
to cut down the number of cigarettes smoked and their intake
of carbon monoxide by using NRT as a harm reduction aid.• There is not enough evidence on whether varenicline, bupropi-
on, ecigarettes, behavioural advice alone, snus or other poten-
tial reduced-exposure tobacco products (PREPs) help to reduce
smoking rates, enhance quit rates, or reduce harm in any way
when used as a harm reduction aid.• There is insufficient evidence of a long-term health benefit of
any interventions intended to help people reduce or alter but
not quit tobacco use. However, there is evidence that reduction
supported by NRT can increase the chances of complete cessa-
tion. Bearing this potential benefit in mind, alongside the strong
safety profile of NRT, the benefits of advising smokers unwilling
or unable to quit smoking to reduce their smoking using NRT are
likely to outweigh any disadvantages, given that the alternative
is likely to be no action.
Implications for research• The tobacco research field has developed a standard for assess-
ing smoking abstinence (the Russell Standard) aimed at improv-
ing the reporting of smoking cessation trials (West 2005). The to-
bacco harm reduction field would benefit from developing sim-
ilar standards to improve the consistency, quality and relevance
of outcomes reported in this area.• More high-quality studies with long-term follow-up are required,
to aid the development of public health guidance, particularly
considering the debate in the field and the emergence of eciga-
rettes.• New studies should ensure that they report all outcomes across
randomized groups, so that all of the intervention effects can be
considered. This should accompany comparisons between suc-
cessful and unsuccessful reducers, as this will help to explore the
role of smoking reduction in mediating any effects of harm re-
duction interventions on cessation.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Country: Australia
Recruitment: community volunteers
Design: Double-blind, placebo-controlled randomized trial
Dates of study: 1999-2001
Participants 436 smokers (≥ 15 CPD) not intending to quit (218 placebo; 218 NRT)
Av. age 44, av. CPD 28, CO 26
Interventions 1. Nicotine gum, 2mg or 4mg according to dependence score, for 4m
2. Placebo
Outcomes Reduction in CPD: sustained > 50% at 12m
Abstinence: PP at 12m
Validation: Reduction by reduced CO from baseline
Notes Unpublished study. Data from Pfizer summary; therefore limited details
Funding declaration and conflict of interest: the study was conducted by Pfizer- the drug company who
manufacture Nicorette NRT products
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Trial described as randomized but method not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind with placebo control, but no other details specified
Australia NNCG-017 
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 436 participants were equally distributed in comparable groups. 276 attended
the last follow-up; but N in each group not specified
Australia NNCG-017  (Continued)
 
 
Methods Country: Germany and Switzerland
Recruitment: community volunteers
Design: Double-blind, placebo-controlled randomized trial
Study dates: 2001-2002
Participants 364 smokers (≥ 20 CPD) not intending to quit, at least 1 failed quit attempt within 2 yrs but not within
6m (184 NRT; 180 placebo)
41% F, av age 43, av. CPD 28
Interventions 1. Nicotine gum, 4 mg for up to 12m, 6 - 24 pieces daily
2. Placebo gum
Aim to reduce as much as possible, 50% not given as objective. Counselling on reduction provided at 9
clinic visits
Outcomes Reduction in CPD: sustained > 50%at 13m
Reduction in CO: Sustained > 20% at 13m
% CO reduction from baseline at 13m (For 55 intervention, 39 control participants including quitters
who completed all visits)
Also % reduction in CPD, cotinine, thiocyanate
Abstinence: PP at 13m
Validation: CO at all visits
Notes Sustained quitters (2 intervention, 0 control) included with reducers
Attrition: 138 (75%) gum vs 111 (62%) placebo reached at 13m
Funding declaration: the study was funded by Pfizer- the drug company who manufacture Nicorette
NRT products.
Conflicts of interest: "Anil Batra has received research funding from Pfizer Consumer Healthcare for this
and other research projects. Karl Klingler has received research funding from Pfizer Consumer Health-
care for this research project. Björn Landfeldt, Åke Westin, and Tobias Danielsson are employees of
Pfizer Consumer Healthcare. Hubertus M. Friederich has no conflict of interest to declare."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind with placebo control, but no other details specified
Incomplete outcome data
(attrition bias) 
Low risk 98 nicotine participants (53%) and 69 placebo participants (38%) were seen for
the 13m follow-up. A further 82 participants were followed up by telephone or
Batra 2005 
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All outcomes letter at 13m, yielding a total of 249 participants who completed the study (n =
138 in nicotine group and n = 111 in placebo group)
Batra 2005  (Continued)
 
 
Methods Country: USA (community-based clinic)
Recruitment: newspaper advertisements
Design: parallel-group RCT
Study dates: not stated
Participants 135 smokers (80 PREP group; 55 usual smoking group) of at least 10 CPD for past year, not interested
in quitting in next 6m, CO ≥ 25 ppm or saliva cotinine ≥ 100 ng/ml, 18 - 70 years old, healthy based on
medical history and screening blood tests
53% F; av. age 37; av. CPD 23; CO 21 ppm
Interventions 1. Reduced nicotine content-cigarettes (RNC): participants provided with 5 types of progressively lower
nicotine content-cigarettes. First 4 levels smoked for 4 weeks each, lowest then smoked for 6m. Target
nicotine level per cigarette 12, 8, 4, 2 and 1 mg as progressed through study. Were told to smoke study
cigarettes as desired, but not to smoke any other type of cigarette and not to use other forms of tobac-
co or nicotine medications.
2. Usual brand control: smoke own cigarettes as normal
Both groups attended face-to-face bi-weekly visits at a community based clinic
Outcomes Markers of consumption: CPD, plasma nicotine, plasma cotinine, expired carbon monoxide
Markers of carcinogens: urine NNAL, urine 3 + 4 hydroxyphenanthrenes, urine 2-Naphol, urine 2-hy-
droxyfluorene, urine 1-hydroxypyrene
Health markers: SBP, heart rate, WBC count, haemoglobin, HDL cholesterol, fibrinogen
Abstinence: 7-day PP, verified biochemically as plasma cotinine concentration of < 14 ng/ml or, if taking
nicotine replacement medication, an expired CO concentration of < 5 ppm
All measured up to 6m
Notes Funding declaration: the National Cancer Institute and National Institute on Drug Abuse, National Insti-
tutes of Health.
Philip Morris provided research cigarettes.
Conflicts of interest: "N.L. Benowitz is a consultant to several pharmaceutical companies that market
medications to aid smoking cessation and has served as a paid expertwitness in litigation against to-
bacco companies. S. Hall has received material support for an ongoing clinical trial from Pfizer. No po-
tential conflicts of interest were disclosed by the other authors."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomized in blocks of 10, but method of sequence generation not specified
Benowitz 2012 
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Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
High risk "The study was not blinded because we wanted to simulate a real world regu-
latory situation in which the nicotine content of cigarettes is progressively de-
creased with the knowledge of the smoker." Non-blinded so at risk of detec-
tion bias. Biomarkers of exposure were used
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Data on losses to follow-up somewhat unclear, but significantly higher propor-
tion lost to follow-up in intervention than control group (27/80 lost interven-
tion, 5/55 lost control). 17 of intervention dropouts leW study due to "not liking
the cigarettes".
Benowitz 2012  (Continued)
 
 
Methods Country: Switzerland (2 hospital pulmonary clinics)
Recruitment: community volunteers
Design: Double-blind, placebo-controlled randomized trial
Study dates: 1997-1999
Participants 400 smokers (200 NRT; 200 placebo), smoking > 15 CPD for 3+ yrs, failed at least 1 serious quit attempt
in past 12m, wanting to reduce smoking as much as possible
52.5% F, av age 46, av. CPD 29, CO 27 ppm
Interventions 1. Nicotine inhalator, 6 - 12 cartridges over 24 hrs. Encouraged to decrease after 4m but use permitted
up to 18m
2. Placebo inhalator (contained menthol only)
Counselling on smoking reduction provided at each clinic visit (1, 2, 3, 6 wks, and 3, 4, 6, 12, 18, 24m).
Smoking cessation was recommended as ultimate goal throughout study
Outcomes Reduction in CPD: > 50%, sustained from week 5 at 24m
Abstinence: sustained from wk 6 at 24m, PP cessation at 24m
(Paper reports outcomes after 4m and 12m, also PP rates)
Validation: Reduction validated by reduced CO from baseline (at 6 wks, 3m, 4m), but amount of reduc-
tion not specified, abstinence verified by CO < 10 ppm from wk 6
Bolliger 2002 reports on health risk markers for 25 successful sustained reducers compared to unsuc-
cessful participants
Notes PP rates of cessation increased through the study
Attrition: 166 (83%) inhaler vs 144 (72%) completed 24m
Funding declaration: Pharmacia and Upjohn Consumer Healthcare, Sweden.
Conflicts of interest: "TD, ÅW, and US are all employed by Pharmacia and Upjohn, Sweden, and AR,
CTB, and JPZ have
received funds for research from them."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated central list
Bolliger 2000 
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Allocation concealment
(selection bias)
Low risk "Independent pharmacists dispensed either active or placebo inhalers". The
placebo inhalers were identical in appearance to the intervention inhalers
Blinding (performance
bias and detection bias) 
All outcomes
Low risk "double blind, placebo controlled". The placebo inhalers were identical in ap-
pearance to the intervention inhalers
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk At 24m follow-up 83% were followed up in the intervention group and 72% in
the placebo group
Bolliger 2000  (Continued)
 
 
Methods Country: Italy
Recruitment: through local newspaper. Study took place at smoking cessation clinic at the Universita di
Catania
Design: parallel-group RCT
Study dates: 2010-2012
Participants 300 smokers (200 in ecig groups; 100 in placebo group). Inclusion criteria: smoked ≥ 10 factory-made
CPD, for at least the past 5 years, aged 18 – 70 years, in good general health; not currently attempting to
quit smoking or wishing to do so in the next 30 days, committed to follow trial procedures
37% F; av. age 44, av. CPD 21, CO 20
Interventions 1. 7.2 mg e-cig: "Categoria" e-cigarette (model ‘‘401’’) 3-piece e-cig model that closely resembles a to-
bacco cigarette. Loaded with "Original" 7.2 mg nicotine cartridges. 12-wk supply of cartridges provid-
ed Participants were given a free e-cigarette kit and were permitted to use the study product ad libitum
throughout the day (up to a maximum of 4 cartridges a day, as recommended by the manufacturer) in
anticipation of reducing the number of CPD smoked. Participants were also asked to fill in a 2-wk study
diary. No emphasis on encouragement, motivation and reward for the smoking cessation effort were
provided, since this study was intended to monitor smokers (not wishing to quit) using e-cigs. After 12
wks participants were informed that no more cartridges would be provided by the investigators, but
that they were advised to continue using their ecigarette if they wished to do so
2. 5.4 mg e-cig: as for group 1 apart from participants received 6 wks of 7.2 mg cartridges and then 6
weeks of "Categoria" 5.4 mg nicotine (1.71, SD 0.09% nicotine).
3. 0 mg e-cig: as for group 1 apart from cartridges were "Original" without nicotine (sweet tobacco aro-
ma), supplied for 12 wks
Outcomes Consumption: CPD; 50%+ reduction in CPD; expired CO
Quit rates: complete self-reported abstinence from tobacco smoking - not even a puH (together with an
exhaled CO concentration of 7 ppm or less) since the previous study visit
All measured to 12m follow-up
Notes Funding declaration: "This research was supported by a grant-in-aid from Lega Italiana AntiFumo. The
study sponsor had no involvement in the study design, collection, analysis, and interpretation of da-
ta, the writing of the manuscript or the decision to submit the manuscript for publication. The e-ciga-
rette supplier had no involvement in the study design, collection, analysis, and interpretation of data,
the writing of the manuscript or the decision to submit the manuscript for publication. The "Categoria"
electronic cigarette kit and cartridges were provided free of charge by the local distributor, Arbi Group
Srl, Italy."
Caponnetto 2013 
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Conflicts of interest: "RP has received lecture fees and research funding from Pfizer and GlaxoSmithK-
line, manufacturers of stop smoking medications. He has served as a consultant for Pfizer and Arbi
Group Srl, the distributor of the CategoriaTM e-Cigarette. The other authors have no relevant conflict
of interest to declare in relation to this work. This does not alter the authors’ adherence to all the PLOS
ONE policies on sharing data and materials."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The randomization sequence was computer-generated by using block size of
15 with an allocation ratio of 5:5:5 for each of the 3 study conditions (A, B, and
C)
Allocation concealment
(selection bias)
Low risk The hospital pharmacy was in charge of randomization and packaging of the
cartridges
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Blinding was ensured by the identical external appearance of the cartridges
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk At 52-wk follow-up 35 of Group A, 37 of group B and 45 of Group C had dropped
out. All participants received their allocated intervention. Overall 225 partic-
ipants (75.0%) returned at wk 12, 211 (70.3%) at wk 24, and 183 (61.0%) for
their final follow-up visit at wk 52. Baseline characteristics of those who were
lost to follow-up were not significantly different from participants who com-
pleted the study, with the exception of gender: at wk 52, men were 71% of par-
ticipants lost to follow-up, while 58% among those still present at wk 52 (P =
0.03, Chi2 test). No significant difference was evident in dropout rates among
study groups at any study visit (Chi2 test)
Caponnetto 2013  (Continued)
 
 
Methods Country: USA
Recruitment: community volunteers
Design: randomized pilot trial
Study dates: not stated
Participants 67 smokers (brief advice 35; reduction 32), smoking > 10 CPD, with an interest in quitting eventually but
not in next 30 days. At least 1 previous attempt. 69% F; av. age 44; av. CPD 24
Interventions 1. Behavioural support to reduce by > 50% in 4 wks. NRT (gum or patch or inhaler) described and of-
fered At 4 wks given brief advice to quit based on US guideline; weekly visits
2. Brief advice to quit at initial visit, NRT provided only if quit date set; weekly visits
Outcomes Change in CPD (50% reduction outcome only given for intervention group)
Abstinence for 7 days at 6m (average reduction in CO only reported at 4 wks)
Notes Main objective of study was to assess whether assistance to reduce enhanced quit rates compared to
advice to quit. Not included in meta-analysis as participants were willing to quit within 6 months (al-
though not immediately)
Funding declaration: "The study was supported by NIDA Grant DA 11557, NIDA Training Grant DA 07242,
and NIDA Senior Scientist Award DA 00450."
Conflicts of interest: not stated
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Non-blinded, behavioural: participants were either asked to reduce with NRT
or given brief advice to quit and used NRT if set a quit date. However, both
groups were provided with NRT and smoking behaviour was biochemically
verified
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not clearly reported
Carpenter 2003  (Continued)
 
 
Methods Country: USA
Recruitment: proactive calls to identify households with smokers
Design: randomized controlled trial
Study dates: not stated
Participants 616 smokers (212 reduction group; 197 motivation group; 207 no intervention), smoking ≥ 10 CPD, not
interested in cessation. 71% F, av.age 40, av. CPD 22, 65% precontemplators
Interventions 1. Behavioural support to reduce by either scheduled or hierarchical reduction. NRT (gum or patch) de-
scribed and offered. At 6 wks given brief advice to quit based on US guideline. NRT offered at wk 6 if
quit date set, NRT no longer available otherwise. 12 - 17 mins at each call
2. Motivational interviewing. '5 Rs' approach (Relevance/ Risks/ Rewards/ Roadblocks/ Repeated). Eligi-
ble for free NRT if quit date set. Mailed self-help materials, counsellor call within 5 days of TQD
3. Control. No intervention, assessment calls only.
Common components: Phone contacts at 0, 3, 6, 24 wks
Outcomes Reduction in CPD excl quitters at 24 wks
PP abstinence at 24 wks
Quit attempts, over 24 hrs and in 6m
Notes Similar objective to Carpenter 2003. Not included in meta-analysis as participants were offered a cessa-
tion intervention after 6 wks of reduction
Funding declaration: "This study was supported by National Institute on Drug Abuse (NIDA) Grant DA
11557 and NIDA Training Grant DA 07242 to Matthew J. Carpenter, and NIDA Senior Scientist Award DA
00450 to John R. Hughes." The nicotine replacemnet therapy was supplied by GlaxoSmithKline Con-
sumer Healthcare.
Conflicts of interest: not stated
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
High risk Behavioural intervention, unblinded; level of support was not equivalent
across all groups, and quit rates where not biochemically validated
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not reported
Carpenter 2004  (Continued)
 
 
Methods Country: China
Recruitment: through announcements in local media and contacting previous cohorts of smokers who
had had cessation counselling. Study took place in smoking cessation clinics with face-to-face coun-
selling
Design: parallel-group RCT
Study dates: 2004-2007
Participants 1154 smokers (928 reduction groups; 226 control group). Inclusion criteria: Chinese, aged 18+ years,
smokes at least 2 CPD, no intention to quit in next 4 wks but interested in reducing smoking, no con-
traindication to NRT, not following other forms of smoking cessation or reduction interventions
16% F, av. age 42, av. CPD 20, av. CO 17
Interventions 1. Reduction & adherence (full intervention): 8 wks free supply of NRT (gum or patch according to par-
ticipant preference).Counselling in smoking reduction and adherence to NRT given. Told to reduce
their smoking; emphasized achieving the ultimate goal of complete cessation by focusing on the im-
portance of smoking reduction before quitting, how reduction is useful and effective when quitting
is difficult, and on how to reduce. A participant-centred intervention utilizing motivational interview-
ing techniques and the 5R approach (relevance, risk, rewards, roadblocks and repetition) was used to
boost motivation. The 3-min ADIN adherence counselling was developed from the guidelines on ad-
herence interventions by the World Health Organization, which emphasizes the importance of adher-
ence to prescribed NRT dosage in the treatment of tobacco dependence, advantages of adherence and
disadvantages of non-adherence, assessment and discussion of the ways to overcome barriers and a
problem-orientated approach to improving adherence. Counselling was provided at baseline, wk 1 and
wk 4. Participants also received a self-help quitting pamphlet, ‘Tips for Quit Smoking’, produced by
Hong Kong Council on Smoking and Health
2. Reduction only: Participants were provided with the same 8-wk free supply of NRT as group 1; how-
ever they were provided counselling in smoking reduction only, with no adherence element. Partici-
pants were told simply to reduce their smoking as in group 1 and were provided with specific reduction
counselling. Counselling was provided at baseline, wk 1 and wk 4. They also received the self-help quit-
ting pamphlet.
3. Control: Participants were not provided with any NRT. They were given simple advice on the health
hazards of smoking and the importance of smoking cessation at baseline, and also received the pam-
phlet supplied to groups 1 and 2
For the purposes of analyses we combined the intervention groups (1 and 2).
Chan 2011 
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Outcomes Consumption: reduction in CPD of at least 50% (validated by exhaled CO level reduction of 1 ppm+
compared to baseline); reduction in CO of at least 50%
Quitting: 7-day point prevalence (validated by exhaled CO level of 9 ppm or less, or urinary cotinine
concentration of 115 ng/ml or less).
All measured at 6m follow-up
Notes Funding declaration and conflicts of interest: "This study was funded by the Health and Health Services
Research Fund, Hong Kong SAR (Project no. 01030611). Nicotine patches/gum provided free of charge
to the subjects were provided free from Pfizer, later named as McNeil AB. Pfizer was not involved in the
design and conduct of the study, in the collection, management, analysis or interpretation of the data,
or in the preparation, review or approval of themanuscript. Moreover,we do not have any
connection of any of the researchers with the tobacco, alcohol, pharmaceutical or gaming industries or
anyone funded substantially by one of these organizations."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The random numbers for group assignment were generated by the research
assistant (not the counsellors) of the project using a personal computer before
participant recruitment
Allocation concealment
(selection bias)
Low risk Randomization was performed by opening of a serially-labelled, opaque and
sealed envelope with a card inside indicating the randomly-allocated group by
a trained smoking cessation counsellor
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Behavioural interventions, so blinding impossible; however, biochemical val-
idation places results at low risk. All participants including control group B
were contacted at 6m by telephone by research assistants blind to group as-
signment of the participants.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There was no statistical difference in retention rates at all 3 time points be-
tween groups A1 and A2 (1 wk: 84.3% vs 83.7%; 4 wks: 72.4% vs 73.7%; 3m:
86.0% vs 85.7%). The retention rate at 6m was statistically higher in group B
(A1: 89.1%; A2: 90.2%; B: 95.6%) but analysis was intention-to-treat
Chan 2011  (Continued)
 
 
Methods Country: Switzerland
Recruitment: community volunteers
Design: Randomized placebo-controlled trial
Study dates: 1999-2007 (including 5 year follow-up)
Participants 923 smokers (265 NRT group; 269 placebo group; 389 no treatment group), smoking ≥ 20 CPD, not in-
tending to quit in next 6m, willing to commit to reduce consumption by half 52% F; av.age 43; av. CPD
29
Interventions 1. Choice of nicotine patch, 4 mg gum, inhaler or combination. 5-day supply of each provided initially,
more could be ordered every 2 wks for 6m
2. Same choice, placebo products
3. Control, no products
Minimal behavioural support: 20-page booklets after enrolment and after 3m survey, 2-page informa-
tion leaflet at each mailing
Etter 2004 
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Outcomes Reduction in CPD: ≥ 50% at 2 yrs (6m and 5-yr outcomes also reported in separate papers). Average re-
duction in CPD also reported
Abstinence: 4 wks at 18m
Validation: none
Notes Placebo group only as control in meta-analysis (the no treatment control group was not included in
meta-analyses); this is conservative for effect of NRT on reduction, but increases effect on abstinence
By 5 yrs there was no significant difference in cessation rates or CPD due to increased cessation and re-
duction in controls.
Funding declaration: "This study was supported by grants from the Swiss National Science Foundation
to JFE (3233-054994.98 and 3200-055141.98) and by the Swiss Federal Office of Public Health. Nicotine
and placebo products were provided by Pharmacia Inc (Helsingborg, Sweden)."
Conflicts of interest: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated list
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Nicotine and placebo products were sent to participants in unbranded pack-
aging, similar in the 2 groups, labelled ‘‘nicotine or placebo.’’ The investiga-
tors had no in-person contact with participants and had only minimal (reac-
tive) telephone contact. All documents sent by mail were identical in the nico-
tine and placebo groups. Thus, participants were not aware of the nature of
the products they received, but the investigators were not blinded. After the
end of the 6m intervention, participants were informed of whether they had
received nicotine or placebo products
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 93%, 93% and 90% of the nicotine, placebo and control groups respectively
were followed up at 2 years
Etter 2004  (Continued)
 
 
Methods Country: USA
Recruitment: HMO members scheduled for outpatient surgery or diagnostic procedure
Design: Randomized controlled trial
Study dates: 2004-2006
Participants 320 smokers (164 intervention; 156 control), smoking > 20 CPD, not interested in quitting smoking; 73%
F, av. age 55, av. CPD 21
Interventions 1. Telephone-based, individualized graduated reduction to 50% or more. Cessation encouraged follow-
ing reduction. 4 phone sessions over 6m, 4 individually-tailored newsletters, 1 targeted newsletter
2. Usual care plus 3 generic health education mailings
Outcomes Reduction: > 50% in CPD, > 50% in CO at 12m (and 3m)
Abstinence: 12m PP
Glasgow 2009 
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Notes Funding declaration: "Funding was provided by the National Cancer Institute, grant #RO1 CA90974-01."
Conflicts of interest: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomized using computer algorithm
Allocation concealment
(selection bias)
Unclear risk Randomized after baseline telephone assessment. Participants who did not at-
tend in person for baseline biochemical samples were excluded from analyses
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Behavioural intervention, so blinding was impossible; however, an attempt
was made to match the intensity and contacts made in the 2 arms and bio-
chemical measurements were used
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 71/391 without baseline samples excluded, similar across groups. 37% inter-
vention and 18% control lost to follow-up, treated as continuing smokers.
Glasgow 2009  (Continued)
 
 
Methods Country: USA, 14 high schools, Minneapolis St Paul
Recruitment: Adolescents smoking ≥ 5 CPD for at least 6m, wanting to reduce, no quit date set for next
2m
Design: randomized, open-label trial
Study dates: 2002-2004
Participants 103 adolescents (34 nicotine patch group; 33 nicotine gum group, 36 placebo group); 58% F, av. age 17,
av. CPD 11.8
Interventions All participants 6 weekly visits 20 - 30 mins incl 10 - 15 mins CBT, medication and reduction from visit 3.
At end of 6 weeks, option to set quit date with medication
1. Nicotine Patch
2. Nicotine gum
3. Folic acid pill (placebo)
Outcomes Reduction: average CPD, average CO, cotinine at 6m
Cessation: 30-day abstinence at 6m
(Outcomes also assessed at end of treatment and 3m)
Notes Not combined with adult NRT studies. Cessation intervention offered after 4 wks of reduction. Cessa-
tion not reported by group, 50% reduction only reported at end of treatment, and not by group. No
treatment effects detected at any follow-up. CPD lower than baseline in all groups at 6m but CO and co-
tinine higher, raising possibility that reducing cigarettes had increased smoke exposure, but could also
have been due to greater free time, variability in smoking patterns and possibly the trajectory towards
increased smoking behaviour. 5/103 reported 30-day abstinence at 6m.
Funding declaration: "Funding for this project was provided by NIH Grants: R01-DA014538 and P50
DA013333. The funding sources did not contribute to developing or conducting the
study"
Hanson 2008 
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Conflicts of interest: "All authors except Dorothy Hatsukami stated that they have no conflicts of inter-
est. Dorothy Hatsukami has the following conflicts of interest: (a) she received an honorarium and trav-
el expense from Pfizer for consulting on their smoking cessation medication, Chantix (12/05), and (b)
she received a joint grant from Nabi Biopharmaceuticals and the National Institute on Drug Abuse to
conduct a clinical trial on the nicotine vaccine."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomized, method not stated
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk A placebo was used but this was not matched to either patch or gum (it was in
pill form). Biological validation was used, but rates were not reported split by
group.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk "Of participants, 91.3% (n = 94/103) completed the study until the end-of-
treatment, 85.1% (n = 80/94) completed the 3-month follow-up visit and 71.3%
(n = 67/94) completed the 6-month follow-up visit." Follow-up rates were high
in general, but not split by treatment arm
Hanson 2008  (Continued)
 
 
Methods Country: USA 12 sites
Recruitment: community volunteers
Design: double-blind, randomized, placebo-controlled trial
Study dates: not stated
Participants 594 smokers (295 bupropion; 299 placebo), smoking ≥ 20 CPD, wanting to reduce amount smoked. Not
quit for > 3m in previous year, at least 2 failed quit attempts including 1 with NRT
45% F; av.age 42; av. CPD 29; av. CO 28
Interventions 1. Bupropion 300 mg/day, 26 wks
2. Placebo
Common components: written materials suggesting reduction techniques, monthly brief individual
counselling, telephone contact day 2, day 12, wk 5 after target reduction date. Participants indicating
a willingness to quit at any time were enrolled in a 7-wk cessation programme with weekly counselling
visits followed by 19 wks of follow-up
Outcomes Reduction > 50% in urine cotinine at 1 yr (denominator 327 excludes 214 who entered cessation arm,
and 53 with missing baseline cotinine)
Reduction > 50% in CPD at 1 yr
Abstinence 6m (denominator 594; 214 entered cessation phase)
Notes 38% of bupropion and 34% of placebo group entered cessation phase. Median time to attempting ces-
sation shorter in bupropion group
Funding declaration: "This study was supported by GlaxoSmithKline, Research Triangle Park, North
Carolina. The sponsor was responsible for finalizing the design of the study and oversight of the re-
search project, had primary responsibility for conducting the data analyses, and reviewed the final pa-
per."
Hatsukami 2004a 
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Conflicts of interest: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated schedule
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Specified to be double-blind trial with matching placebo acting as control, but
no further information given
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There was a high loss to follow-up rate with 31% of the bupropion group and
34% of the placebo group followed up at the 12m visit. However, the rates did
not differ greatly between groups
Hatsukami 2004a  (Continued)
 
 
Methods Country: Germany
Recruitment: community volunteers
Design: double-blind randomized, placebo-controlled trial
Study dates: 2000-2002
Participants 385 (193 of interest in our analyses) healthy adult smokers (96 short-term gum; 96 short-term placebo;
97 long-term gum; 96 long-term placebo), happy to make attempt to change smoking behaviour but
not to quit in the next month; smoked ≥ 15 CPD; had smoked for ≥ 3 yrs; had a CO level of ≥ 15 ppm; had
failed at least 1 serious attempt to quit within the last 24m
50% F; av. age 42; av. CPD 25, av. CO 28
Interventions 1. Nicotine gum, short-term reduction over 4 wks
2. Nicotine gum, long-term reduction up to 9m
3. Placebo, short-term reduction over 4 wks
4. Placebo, long-term reduction up to 9m
Outcomes Reduction > 50% in CPD with CO reduction, sustained at 12m
Abstinence at 12m (PP abstinence used)
Validation: CO < 10 ppm
Notes Included a comparison of 2 schedules of NRT-assisted reduction. Change for 2016 update: participants
in short-term reduction group instructed to reduce and quit over 4 wks, so we have not analysed short-
term reduction group. Comparison made between long-term reduction with gum and long-term reduc-
tion with placebo (2 and 4)
Funding declaration: study conducted by Pharmacia and Upjohn (now merged with and known as Pfiz-
er).
Conflicts of interest: not stated
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Low risk Randomization list generated using a computer programme
Allocation concealment
(selection bias)
Low risk Sealed envelopes were provided by Pharmacia for each participant and held
by the investigator
Blinding (performance
bias and detection bias) 
All outcomes
Low risk All study medication was identical in appearance and packaging. The desig-
nated person who held the list of participants and medications, and dispensed
medication, was not involved in any other aspect of the study. Investigators
and participants were blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 48% of the active groups and 42% of the placebo groups attended the 12m vis-
it
Haustein 2003  (Continued)
 
 
Methods Country: USA
Recruitment: smokers in 2008 – 2009 in Burlington, VT, USA and Omaha, NE, USA, via newspaper, radio,
and flyer advertisements. Study took place in smoking clinics
Design: parallel-group RCT
Study dates: recruitment 2008-2009
Participants 218 smokers (107 varenicline; 111 placebo). Inclusion criteria: wish to eventually stop smoking, no in-
tention to quit smoking in the next month, daily smoking ≥ 8 CPD, no history of use of varenicline, not
currently using a smoking cessation medication, not currently or planning to be pregnant or breast-
feeding and negative pregnancy test, ≥ 18 years old, no current or past history of medical or psycholog-
ical problems that would, in the judgement of the investigators, place the participant at significant risk
of an AE, including lifetime suicidal attempt or current depression, drink fewer than 16 alcoholic bev-
erages per week, no current use of a sedating medication (to minimize possible psychiatric AEs from
varenicline), no current kidney disease or frequent nausea
36% F; av. age 42; av. CPD 19
Interventions 1. Varenicline: participants provided with varenicline for 2 - 8 wks - 1 pill/day (0.5 mg/day) for the first
3 days, then 2 pills/day (0.5 mg each) for 4 days, and then 2 pills/day (1.0 mg each) for the remainder
of treatment. The clinician stated participants should take the medication for at least 2 weeks unless
they had significant side effects, and they were encouraged to use it for up to 8 weeks. Brief counselling
about reduction was given at baseline, 2, 4 and 8 wks. Participants were told varenicline would help
them to reduce CPD, but it is unclear whether reducing improves health. At wk 2 they were encouraged
to reduce CPD for the next 2 wks; however the clinician encouraged smoking reduction only to a degree
that did not cause significant craving or withdrawal. If they agreed the clinician discussed 2 reduction
methods: (a) systematically increasing the minimum amount of time between cigarettes, and (b) rank-
ordering cigarettes from easiest to give up to hardest and systematically foregoing easiest to hardest
cigarettes. The clinician suggested the participant set a very achievable initial goal (e.g. reduce by 5 cig-
arettes over the next 2 wks) to increase the chances of initial success. At all sessions, participants were
asked if they had made a quit attempt since the last session but were never explicitly advised to quit. At
the 4-wk visit, the clinician. encouraged smokers to either maintain that level of smoking, or set a new
reduction goal. At the last visit at 8 wks, the clinician reminded participants that they would not be pro-
vided with further medication unless they set a quit date in the next 2 wks. If during any visit, partici-
pants stated they planned to try to stop smoking or had recently quit and were still abstinent, the ses-
sion did not focus on reduction but rather on methods to prepare for or maintain abstinence.
Hughes 2011 
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2. Placebo: as in group ,1 but participants were provided with placebo medication rather than vareni-
cline
Outcomes Consumption: self-report 50%+ reduction in CPD (only measured to 2m follow-up)
Quitting: 7-day PP at 6m follow-up (validated by exhaled CO < 10 ppm)
Adverse effects: serious adverse events (monitored throughout study)
Notes Funding declaration: "Pfizer Inc. via an unrestricted grant plus provided medication and placebo; Se-
nior Scientist Award DA-000490 to J.R.H. and grant DA011557 to J.R.H.; and the Larson Endowment at
the University of Nebraska Medical Center to S.I.R."
Conflicts of interest: "Dr Hughes is currently employed by The University of Vermont and Fletcher Allen
Health Care. In the last 3 years, he received research grants from the National Institute on Health and
Pfizer Pharmaceuticals and accepted honoraria or consulting fees from Abbot Pharmaceuticals, Acad-
emy for Educational Development, Acrux DDS, Aradigm, American Academy of Addiction Psychia-
try, American Psychiatric Association, Atrium, Cambridge Consulting, Celtic Pharmaceuticals, Cline,
Davis, and Mann, Constella Group, Concepts in Medicine, Consultants in Behavior Change, Cowen Inc.,
Cygnus, Edelman PR, EPI-Q, Evotec, Exchange Limited, Fagerstrom Consulting, Free and Clear, Health
Learning Systems, Healthwise, Insyght, Invivodata, Johns Hopkins University, J Reckner, Maine Medical
Center, McNeil Pharmaceuticals, Nabi Pharmaceuticals, Novartis Pharmaceuticals, Oglivy Health PR,
Pfizer Pharmaceuticals, Pinney Associates, Reuters, Shire Health London, Temple University of Health
Sciences, United Biosource, University of Arkansas, University of Auckland, University of Cantabria, Uni-
versity of Greifswald, University of Kentucky, University of Madrid Medical School, U.S. National Insti-
tutes of Health, and Xenova and ZS Associates. Dr. Rennard is currently employed by the University of
Nebraska Medical Center, Omaha Nebraska. In the last 3 years, he has received research grants/con-
tracts from Almirall, Biomark, Centocor, GSK, the Institute for Science and Health, Lorrilard, Mpex,
Nabi, Novartis, Pfizer, RJReynolds, Roche, Astellas, AstraZeneca, Philip Morris, the National Heart Lung
and Blood Institute, and the National Institute for Environmental Health Sciences. He has received hon-
oraria for consulting or for speaking from Abbott, Almirall, Altana, Anthera, Aradigm, AstraZeneca, Bi-
olipos, BoehringerIngelheim, Centocor, Critical Therapeutics, GSK, Johnson and Johnson, Novartis,
Otsuka, Parengenix, Pfizer, Quintiles, Roche, Sanofi, Schering, TargeGen, Theradvance, UBS, Talecris,
Dey, Nycomed, Pharmaxis the American College of Chest Physicians, the American Board of Internal
Medicine, and the American Thoracic Society. Karl Fagerstrom is president of Fagerstrom Consulting
and has, over the last 3 years, received honoraria and speaking fees from Novartis, Niconovum, Pfiz-
er, Independent Pharmaceutica, McNeil, Institute for Science and Health and various professional net-
works, universities, and scientific organizations. Peter Callas, James Fingar, and Sandy Talbot have no
disclosures."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "One of the authors (PC) randomized study IDs, stratifying by study site. Block
sizes of four were used within each site to ensure an approximately equal dis-
tribution to active and placebo groups within site." However, does not specify
how participants were randomized
Allocation concealment
(selection bias)
Low risk The list of IDs and assignment was sent to either a pharmacist (at Nebraska
site) or a research assistant (at Vermont site) who prepared the appropriate
aliquot of pills for each ID. Neither PC nor the pharmacist/research assistant
had contact with participants during the study. At each site, consented partici-
pants were assigned to the next ID in sequence
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Placebo control used for blinding. Clinicians were unaware of the randomiza-
tion details (e.g. block size) and were blinded to participant condition. Fol-
low-up phone calls were made by research assistants blind to study conditions
Hughes 2011  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The study flow diagram only goes up to 2m follow-up, i.e. no information to 6
months However, dropout is almost equal at this point
Hughes 2011  (Continued)
 
 
Methods Country: Serbia
Recruitment: Participants were recruited through posters and other printed material distributed at
near the study sites, and by word-of-mouth. The 2 sites were occupational health centres located at the
head office of a large Serbian corporation (NIS-Jugopetrol) and at a major research institution in Bel-
grade (Vinča Institute of Nuclear Sciences)
Design: Parallel-group RCT
Study dates: 2008-2010
Participants 319 smokers (158 snus; 161 placebo). Inclusion criteria: aged between 20 and 65 years, history of dai-
ly smoking for < 1 yr, an average consumption of > 10 CPD during the past month, motivation to sub-
stantially reduce or quit smoking, good general health, acceptance not to take pharmaceutical nicotine
products or any other non-protocol treatment to facilitate smoking cessation during the study period
62% F; av. age 44; av. CPD 27
Interventions 1. Snus: participants were provided with snus throughout the 48-wk study period. The snus was manu-
factured by Swedish Match AB according to the GothiaTek® standard. Participants could choose from
2 different sachet sizes (0.5 g and 1 g) and 2 different flavours (liquorice and eucalyptus). Whenever
they felt an urge to smoke, participants were instructed to take a sachet of their allocated product. The
number of sachets consumed each day was determined by the participants themselves. There was no
prescribed tapering of product usage. Potential participants were invited to seminars on the health
risks associated with smoking and available smoking cessation strategies. The physiological effects
of nicotine were outlined, and an account given of the Swedish experience with snus including poten-
tial health risks associated with smokeless tobacco products. Participants were instructed to cut down
on smoking as much as possible or quit smoking completely by replacing as many cigarettes as possi-
ble with their allocated study product. Those who managed to achieve the protocol definition of a sub-
stantial smoking reduction at the wk 24 visit or who had quit completely, continued in the trial up to 48
wks. During wks 25 - 48 they were actively instructed to quit smoking completely. Participants who did
not meet the protocol criteria for smoking reduction at the wk-24 visit were counted as treatment fail-
ures in all efficacy analyses and were not actively followed after wk 24
2. Placebo: As for group 1 but using placebo rather than snus product; they were almost identical to the
snus products in physical appearance, mouth feel, pH, flavouring, and other sensory characteristics but
they did not contain tobacco or nicotine
Outcomes Consumption: salivary cotinine; exhaled CO; CPD reduction of 50%+ (verified by a reduced concentra-
tion of CO in exhaled air of at least 1 ppm), CPD reduction of 75%+
Quitting: 7-day PP verified by exhaled CO of < 10 ppm at 24 wks. We are only interested in data up to 24
wks as people were withdrawn after this if they had not reduced
Health markers: BP (systolic and diastolic), body weight, BMI, pulmonary function (FEV 1.0, FVC, FEV%)
Adverse effects: serious adverse events, adverse events, treatment-related adverse events and adverse
events leading to discontinuation of treatment
Notes Funding declaration: "The trial was officially sponsored by Swedish Match AB, Stockholm, Sweden.
Sponsor provided funding, study products (snus and placebo snus), and study equipment. External
contractors paid by the sponsor provided monitoring, data handling, and all statistical analyses (i3 Re-
search, i3 Statprobe)."
Joksić 2011 
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Conflicts of interest: "LER is an employee of Swedish Match AB. GJ, VST, RA, and RN received honoraria
from Swedish Match AB for their work with this trial, but declare no other conflict of interest."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk With stratification by centre, and using a block size of 6, a predefined, central,
computer-generated randomization sequence assigned participants in a 1:1
ratio to receive snus or matching placebo
Allocation concealment
(selection bias)
Low risk Randomization was done by consecutively associating each included partici-
pant’s identifiers with a unique, computer-generated sequential number. Lists
at the study sites linked these numbers to specific study products, i.e. snus or
placebo. At the sites all study products were identified solely by identification
numbers which ensured that both participants and investigators were blinded
to treatment assignments
Blinding (performance
bias and detection bias) 
All outcomes
Low risk The placebo snus products were almost identical to the snus products in phys-
ical appearance, mouth feel, pH, flavouring, and other sensory characteristics
but they did not contain tobacco or nicotine. All study products were identified
solely by identification numbers which ensured that both participants and in-
vestigators were blinded to treatment assignments
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk This is judged low for the data extracted as we have only looked at outcomes
to 24 wks (dropout 26/158 (16%) in snus and 23/161 (14%) in placebo). After
this time point all participants who had not reduced by 50% or quit were with-
drawn. If we had extracted past 24 weeks, risk of bias would have been judged
as high
Joksić 2011  (Continued)
 
 
Methods Country: USA, Veterans Affairs Medical Centres
Recruitment: Community volunteers and referrals and invited people with cardiovascular disorder
Design: RCT
Study dates: not stated
Participants 152 smokers (78 reduction group; 74 usual care), smoked ≥ 15 CPD, unwilling or uninterested in setting
quit date in next 30 days; 12% F, av. age 58, 27 CPD, av. 6 previous quit attempts
Interventions 1. Counselling to encourage reduction by ≥ 50 CPD, at 1, 2 wks and 1, 2, 3, 4, 6, 12, 18m, additional vis-
its after 4m if further interest. Encouraged to use up to 6 pieces of 4 mg nicotine gum, or patches if need
for gum greater. (88% used some form of NRT)
2. Control (usual care): single brief session emphasizing importance of abstinence and encouragement
to seek cessation assistance
Outcomes Reduction > 50% in CPD at 18m, absolute reduction in CPD
Abstinence at 18m (PP)
Biomarkers: CO, urine cotinine, urine nicotine
Other clinical markers: WBC count, NNAL, NNK. QoL, walk test
Adverse events
Notes 5 in Control required urgent cardiac care at 6m vs 0 Intervention. No differences in any clinical or QoL
outcomes. Error in control group denominator corrected for 2016 update (from 78 to 74)
Joseph 2008 
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Funding declaration: "This study was supported by funding from the National Cancer Institute and Na-
tional Institute Drug Abuse Grant DA13333-02."
Conflicts of interest: "The authors do not have any conflicts of interest pertaining to this work."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated, block size 10 by site
Allocation concealment
(selection bias)
Low risk Sealed envelope opened after enrolment
Blinding (performance
bias and detection bias) 
All outcomes
High risk Behavioural intervention meant blinding was not possible. Biochemical verifi-
cation was used, but intervention group intervention received NRT and control
did not
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 64% - 68% followed at 18m, no significant differences between groups
Joseph 2008  (Continued)
 
 
Methods Country: Czech Republic, 2 medical centres
Recruitment: community volunteers willing to control their smoking. Information but equal emphasis
on cessation and reduction
Design: double-blind placebo-controlled RCT; 2:1 active: placebo ratio
Study dates: not stated
Participants 314 smokers (209 NRT; 105 placebo), smoking ≥ 15 CPD, with at least 1 failed quit attempt, did not have
to be motivated to quit. Excludes 11 enrolled who failed to attend baseline visit
58% F, av. age 46, av. CPD 25
Interventions 1. Choice of 4 mg nicotine gum (up to 24/day) or 10 mg nicotine inhaler (6 - 12 daily) for up to 6m with
further 3m tapering
2. Choice of placebo gum or placebo inhaler
Common components: brief behavioural cessation/reduction support at clinic visits (9 scheduled)
Outcomes Sustained > 50% reduction in CPD from 6 - 12m (excluding sustained abstainers)
Sustained abstinence from 6 - 12m (12m PP also reported)
CVD risk factors assessed but not reported yet
Validation: cessation: CO < 10ppm, reduction; any reduction in CO
Notes Cessation was recommended but not mandatory for participation. Reduction was an alternative for
participants unable to quit
First included as 'Kralikova 2002' based on data from conference abstract and draW paper. PP replaced
by 6 - 12m sustained abstinence in 2010 update.
Funding declaration: "This study was funded by McNeil AB, Helsingborg, Sweden. McNeil AB manufac-
tures a range of nicotine replacement products, including nicotine gum and nicotine inhaler."
Conflicts of interest: "Eva Kralikova and Jiri Kozak received funding from McNeil AB to perform this
study (and have previously received payment from other pharmaceutical companies).
Kralikova 2009 
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Thomas Rasmussen and Gunnar Gustavsson are employees of McNeil AB. Jacques Le Houezec is a con-
sultant in tobacco dependence for both the pharmaceutical industry and the public sector."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind, but no other detail given. The placebo groups re-
ceived matching treatment that did not contain nicotine
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Follow-up rates at 12 months not provided.
Kralikova 2009  (Continued)
 
 
Methods Country: USA, Clinical research centre and community
Recruitment: Volunteers for a paid study of effects of different smoking devices, willing to switch from
conventional cigarettes for an extended period
Design: RCT
Study dates: 2003
Participants 225 regular smokers randomised (77 full flavor group; 73 light group; 75 ultra light group), smoking 10 -
30 full-strength CPD (15 mg tar). 166 completed phase 1 of study and continued to phase 2.
24% F; av. age 35; av. CPD 20
Interventions Test of switching to low-tar cigarettes: Participants continued smoking Marlboro Full Flavour ciga-
rettes, or switched to Marlboro Lights (ML) or Marlboro Ultra Lights
Outcomes Biomarkers of exposure and harm; urine nicotine equivalents, cotinine, NNAL, 1-OHP, urine mutagenic-
ity, COHb, S-PMA, 3-PMA, Inter-PuH Interval. Longest follow-up 24 wks, measures taken daily for 8 days
then 4-weekly
Notes Funded declaration: "All test cigarettes used during the short- and long-term phases of the study were
provided by Philip Morris USA." No further information given.
Conflicts of interest: Study conduct and data analysis was carried out by MDS Pharma Services, Lincoln,
Nebraska. No further information given.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomized, method not described
Mendes 2008 
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Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
High risk Non-blinded so at risk of performance bias; biomarkers of exposure were used
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 26% of those randomized to phase 1 study did not enter phase 2. Higher
dropout from low-tar cigarette groups by end of study
Mendes 2008  (Continued)
 
 
Methods Country: Belgium
Recruitment: participants were electively hospitalized (smoking) adults, recruited from ENT, trauma,
neurosurgery, pulmonology, gynaecology, vascular surgery and urology wards in 4 academic hospitals
in Flanders, Belgium
Design: parallel-group, placebo-controlled RCT
Study dates: 2006-2008
Participants 296 smokers (150 patch; 146 placebo). Inclusion criteria: > 18 years, smoking minimum of 15 CPD for
3 yrs and 10 CPD during the 7 days before admission to hospital, life expectancy of a minimum 1 year,
conscious, able to read/sign consent form, hospitalization of at least 72 hours, agreement of treating
physician and anaesthesiologist
67% F, av. age 50, av. CPD 20
Interventions 1. Nicotine patch: Nicotine substitution provided for smoking whilst participants were in hospital. After
randomization participants were offered nicotine patch (15 mg/16-hr) until discharge for a maximum
of 7 days, alongside brief counselling after randomization (20 - 30 min session and a booklet (Belgian
Foundation against Cancer)
2. Placebo patch: as for group 1 but with placebo rather than nicotine patch
Outcomes Quitting: self-reported smoking cessation to 6m follow-up (no more information reported on definition
of abstinence; abstract and presentation slides only data source)
Notes A study of temporary abstinence during a period of hospitalization
Funding declaration: Funded by the Research Foundation - Flanders (PWO), Korn Op Tegen Kanker, and
McNeil AB, Sweden
Conflicts of interest: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "random", no further information provided
Allocation concealment
(selection bias)
Unclear risk States "double blinded" but does not explain how blinding is achieved
Blinding (performance
bias and detection bias) 
Unclear risk States "double blinded" but does not explain how blinding is achieved
Nackaerts 2009 
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Relatively low loss to follow-up, similar across both groups (138/150 followed
up in intervention versus 130/146 followed up in control). However, par-
ticipants were randomized (N = 359) and then 63 deemed ineligible, so the
ITT population is reported as 296. We cannot tell whether ineligibility was
matched between groups
Nackaerts 2009  (Continued)
 
 
Methods Country: USA, 3 sites
Recruitment: community volunteers
Design: double-blind RCT
Study dates: 1999-2001
Participants 429 smokers (215 NRT; 214 placebo), smoking ≥ 20 CPD, interested in reducing cigarette consumption,
excluded if planned to quit in next 4 wks, or 9 or 10 on Contemplation Ladder
55% F, av.age 45, av.CPD 30
Interventions 1. Nicotine inhalator 10 mg ad lib, recommended 6 - 12/day, for up to 12m. Cessation recommended
from 6m
2. Placebo
Common components: 9 clinic visits over 15m
Outcomes Sustained reduction by > 50% from 4 wks to 15m
PP abstinence at 15m
CVD risk factors ,WBC, HDL, LDL, fibrinogen, C4RP at 4m reported for reducers + abstainers, not by con-
dition
Validation: CO for reduction
Notes Some data from Pfizer internal report since only graph for reduction in published paper
15m outcomes used. 12m gives lower effect
Funding declaration: Study carried out by Pfizer.
Conflicts of interest: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind. The matched placebo inhaler was identical to the
active treatment with the nicotine excluded. No further information given
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 41% of the active group and 30% of the placebo group completed the 15m
study
Rennard 2006 
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Methods Country: USA
Recruitment: community volunteers
Design: RCT
Study dates: not stated
Participants 93 smokers (44 computerized reduction; 49 self-help), smoking ≥ 15 CPD, interested in reduction, 2 fail-
ures in planned quit attempts, not quit > 30 days in past yr
44% F, av.age 45, av. CPD 27, av. 5.6 previous attempts, av. 32m since last
Interventions 1. Computerized scheduled gradual reduction over 2 wks to 50% goal with programme covering com-
puter operation, harm reduction, self-management and relapse prevention techniques
2. Self-help treatment guide instructing in gradual reduction using selective elimination of cigarettes
Outcomes Reduction ≥ 50% at 12m, (mean % reduction)
PP abstinence at 12m
Validation: CO < 10 ppm
Notes Not shown in graphs
18.2% reduced (mean 38%) vs 18.4% (mean 35%)
5/44 (11.4%) vs 3/49 (6.1%) quit at 12m (NSS)
Funding declaration: "This study was supported by a grant from the National Cancer Institute
(R43CA83451)."
Conflicts of interest: "Institution where work was carried out: Personal Improvement Computer Sys-
tems (PICS). All authors were employees of PICS, a commercial interest developing computerized
smoking reduction products."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
High risk Could not blind due to intervention design, so performance bias a risk. CO vali-
dation was used
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The completion rate was 61% at 12m follow-up, but this is not reported by
group allocation
Riley 2002 
 
 
Methods Country: USA, clinical research centre and community
Recruitment: Volunteers for a paid study of effects of different smoking devices, willing to switch from
conventional cigarettes for an extended period
Design: RCT
Roethig 2008 
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Study dates: not stated
Participants 97 regular smokers (64 EHCSS; 33 conventional cigs), smoking 10 - 40 low-tar (1 - 7 mg) cigarettes daily
for at least 10 years, 25 - 65 years of age.
54% F; av. age 42; av. CPD 24
Interventions Test of switching to 2nd generation electronically heated cigarette smoking system (EHCSS).
Controls continued to smoke conventional cigs
Outcomes Biomarkers of exposure included plasma cotinine, carboxyhaemoglobin (COHb), urine nicotine and
major metabolites, total NNAL, NNK, total 1-OHP, and urine mutagenicity
Cardiovascular risk biomarkers included haemoglobin (Hb), hematocrit (Hct), red blood cell count,
WBC, fibrinogen, HDL cholesterol, LDL cholesterol, triglycerides, high-sensitivity C-reactive protein (hs-
CRP)
Longest follow-up 12m, also assessed at 2 wks, 1, 2, 3, 4, 5, 6, 9m
Notes Funded declaration: "Financial support provided by Philip Morris USA." Cigarettes provided free to par-
ticipants by Phillip Morris.
Conflicts of interest: MDS Pharma Services were responsible for clinical conduct and bioanalytical and
statistical analyses. No further information given.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
High risk Non-blinded so at risk of performance bias; biomarkers of exposure were used
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 50/64 using EHCSS completed last visit, 59/64 evaluable. 33/33 control evalu-
able
Roethig 2008  (Continued)
 
 
Methods Country: USA, clinical research centre and community
Recruitment: Volunteers for a paid study of effects of different types of cigarette, willing to switch from
their usual cigarettes for an extended period
Design: RCT
Study dates: not stated
Participants 97 regular smokers (45 6mg test cigarettes; 21 6mg conventional cigarettes; 16 11mg test cigarettes; 15
11mg test cigarettes), smoking 10 - 30 6 mg or 11 mg tar cigarettes daily; approximately 18 CPD at base-
line
Interventions 2 substudies of switching to carbon-filtered cigarettes with 6 mg or 11 mg tar. Controls continued to
smoke conventional cigs with same tar levels. Only interested in long-term studies
Sarkar 2008 
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Outcomes Biomarkers of exposure to gas phase: acrolein, 1,3-butadiene, benzene, measured by the 24-hr urinary
excretion of metabolites. Biomarkers of exposure to particulate phase: nicotine, NNK, pyrene
Biomarkets of cardiovascular risk: LDL cholesterol, HDL cholesterol, and triglycerides
Longest follow-up 24 wks, also 4, 8, 12, 16, 20 wks 
Notes Funding declaration: "The research was funded by Philip Morris USA." The cigarettes were provided
free to participants by Phillip Morris USA.
Conflicts of interest: "The authors have no additional competing interests to declare." The study, plus
bioanalytical and statistical analyses were conducted by MDS Pharma Services.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
High risk Non-blinded so at risk of performance bias; biomarkers of exposure were used.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 2 studies are reported (LT-6 & LT-11) In LT-6, 45 took part in the intervention
arm and 21 in the control arm. Of these 80% of the intervention group and 81%
of the control group completed the study. In LT-11, 16 took part in the interven-
tion arm and 15 in the control arm. Of these 94% of the intervention group and
53% of the control group completed the study. Therefore differential dropout
was apparent between groups.
Sarkar 2008  (Continued)
 
 
Methods Country: Denmark
Recruitment: community volunteers for smoking reduction
Design: placebo-controlled RCT
Study dates: 1999-2001
Participants 411 smokers (205 NRT; 206 placebo), smoking ≥ 15 CPD, interested in reducing but unwilling/unable to
give up
62% F, av. age 45, av. CPD 24
Interventions 1. Nicotine gum, 2 mg if FTND = 5, 4 mg if 6 - 10, for up to 12m
2. Placebo gum
Common components: brief individual information on smoking reduction, effects on health, sugges-
tions on ways to reduce number of cigs, cessation recommended as ultimate goal
Outcomes Sustained (4, 12, 24m) and PP reduction of > 50% at 24m
CPD,CO, cotinine and thiocyanate average % of baseline by treatment group in continuing participants
at 24m. Also mean values by reducer categories
PP abstinence at 24m
Validation: CO < 10 ppm
Notes PP reduction gives a more conservative treatment effect
Wennike 2003 
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Funding declaration: "This study was supported by a grant from Pharmacia AB, Sweden."
Conflicts of interest: Not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind. The placebo gum was similar in appearance and
taste, but contained no nicotine. No further information given
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 40% of the treatment group and 35% of the placebo group completed the
study
Wennike 2003  (Continued)
av: average
BMI: body mass index
BP: blood pressure
C4RP: C4-reactive protein
CPD: cigarettes per day
CO: carbon monoxide
CVD: Cardiovascular disease
EHCSS: electrically heated cigarette smoking system
F: female
FTND: Fagerström Test for Nicotine Dependence
HDL: high-density lipoprotein
HMO: health maintenance organization
LDL: low-density lipoprotein
m: month(s)
NNAL:
NNK: nicotine-derived nitrosamine ketone
NRT: nicotine replacement therapy
NSS: not statistically significant
PP: point prevalence (abstinent during a limited defined period)
ppm: parts per million
SBP: systolic blood pressure
TQD: target quit date
WBC: white blood cells
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adriaens 2014 All groups used electronic cigarettes. There was some variation between the experimental and con-
trol group (in the intensity of instructions), and follow-up points were not comparable
Applegate 2004 Reported as a conference abstract. Insufficient data to include
Baker 2006 Reduction was a secondary outcome in a trial of a cessation-focused intervention
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Study Reason for exclusion
Barrett 2011 Did not provide follow-up of 6m or more
Benowitz 2005 Short-term (3-wk) cross-over trial comparing conventional and 'light' cigarettes. Outcomes were
biomarker exposures
Bloch 2010 Did not provide follow-up of 6m or more
Borland 1999 Intervention was intended to assist smokers in coping with workplace smoking bans by learning to
cope with smoking behaviour. Smoking reduction was reported as change in CPD or any reduction.
Use of intervention was low
Breland 2006 Short-term cross-over trial comparing Advance, Eclipse, own-brand cigarettes, or no cigarettes.
Outcomes were biomarker exposures
Caldwell 2010 Short-term cross-over trial comparing snus, Zonnic and nicotine gum. Outcomes were urges to
smoke, withdrawal symptoms and the sensory quality of the products
Chiou 2013 Did not provide follow-up of 6m or more
Chisolm 2013 Data on smoking behaviour was observational. Intervention was not testing tobacco harm reduc-
tion
Cunningham 2006 Short-term (3m) follow-up. Trial compared a questionnaire containing tips on safer smoking with a
control asking about harm reduction activities
Dautzenberg 2001 Participants underwent a smoking cessation programme
Ebbert 2015 Although participants were not willing or able to quit smoking within the next month they did need
to be willing to reduce smoking and make a quit attempt within the next 3m at point of recruitment
Eliasson 2001 Uncontrolled short-term study of reduction and cessation assisted by nicotine nasal spray
Etter 2003 Outcome was effect of information about NRT and cigarette use on motivation to quit
Fagerström 1997 Short-term (5-wk) follow-up. Test of NRT for smoking reduction. Participants tried out different
types of NRT, then chose or were assigned a product in a cross-over design. No non-NRT control. No
serious adverse effects reported
Fagerström 2000 Short-term (6-wk) study. Compared a potentially reduced exposure product (Eclipse), nicotine in-
haler or usual cigarettes
Fagerström 2002b Short-term (14 wk) follow-up. Participants enrolled in a previous study (Fagerström 2000) self-se-
lected a potentially reduced exposure product (Eclipse), nicotine inhaler or usual cigarettes
Fatemi 2005 Short-term (8 wk) cross-over study of bupropion or placebo for smoking reduction in people with
schizophrenia
Fatemi 2013 Did not provide follow-up of 6m or more
Feng 2006 Short-term (8-day) study comparing biomarkers of exposure from conventional cigarettes, low tar,
or electrically heated cigs
Frost 1995 Study to assess compensation when smoking low-tar brand
Frost-Pineda 2008 Short-term (12-wk) study comparing biomarkers in smokers of conventional cigarettes and smok-
ers using an ECHSS
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Study Reason for exclusion
Gelkopf 2012 Did not provide follow-up of 6m or more
Glasgow 1983 No long-term follow-up of wait list control group. Smoking reduction was maintained at 6m fol-
low-up in both treatment groups
Gray 2008 Laboratory study and short-term (20-day) study of toxicant exposure of different smokeless tobac-
co products
Hagen 2011 Both intervention groups had access to the tested intervention prior to the 1-year follow-up (the
control group were also given the albendazole medication 2 weeks following their placebo medica-
tion)
Hatsukami 2004b Short-term (6-wk) study comparing the effect on carcinogen exposure of switching from cigarette
smoking to either the OMNI cigarette or a nicotine patch, and switching from smokeless tobacco to
Swedish snus or a nicotine patch
Hatsukami 2005 Short-term (12-wk) study using NRT to reduce smoking with a target of 75% reduction. A wait list
control delayed reduction for 6 wks. Outcomes were change in multiple biomarkers amongst suc-
cessful reducers
Hatsukami 2007b Short-term (12-wk) intervention for switching smokeless tobacco brands
Hatsukami 2008 Short-term (12-wk) intervention for reducing smokeless tobacco use
Hatsukami 2010 Short-term (6-wk) parallel study comparing effects of reduced nicotine cigarettes, very low-nico-
tine cigarettes or nicotine lozenges on compensatory smoking behaviour, biomarkers of exposure,
tobacco dependence, tobacco withdrawal and abstinence rate
Hatsukami 2016 Although in the first instance the aim of the study was to get participants to switch from cigarettes
to NRT or snus, the ultimate goal was to wean participants oH NRT and snus. The aim of the study
was cessation rather than harm reduction
Hughes 2004 Short-term (12-wk) cross-over study comparing the effect on smoking behaviour and toxin expo-
sure of conventional cigarette smoking versus the Omni cigarette
Hurt 2000 Uncontrolled study. Nicotine inhaler used to assist smoking reduction with follow-up at 24 wks
Hussain 2010 Did not provide follow-up of 6m or more
Jimenez-Ruiz 2002 Uncontrolled study. Nicotine gum used to assist smoking reduction with follow-up at 18m
Karem-Hage 2014 Participants receieved a smoking cessation intervention
Kelly 2010 In order to be eligible for inclusion smokers had to want to quit in the next 6m.
Kotlyar 2007 Short-term within-person cross-over study comparing nicotine concentrations, craving, withdrawal
and product liking for 4 PREPs, moist snuH and medicinal nicotine
Lamb 2005 Short-tem study using financial incentives to reward reduced smoking
Lan 2007 Some of the recruited participants were ready to quit at recruitment
Leelarungrayub 2010 Did not provide follow-up of 6m or more
Lichtenstein 2008 Outcomes were cessation and household smoking bans, not smoking reduction
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Study Reason for exclusion
Malchodi 2003 Reduced smoking was a secondary outcome in a trial of a cessation intervention
McKinney 2014 Did not provide follow-up of 6m or more
Mendoza-Baumgart 2007 Short-term (5-wk) study comparing smokeless tobacco products to a nicotine lozenge for people
stopping smoking
NCT01944423 2013 The aim of the intervention was for smokers to quit completely (testing smoking cessation inter-
vention)
Ostroff 2014 The aim of the intervention was for smokers to quit completely (testing smoking cessation inter-
vention)
Pisinger 2005 Study was large population-based study. In the intervention arms those participants unwilling to
quit were provided a different intervention to those willing to quit. However, the control group did
not split participants according to their intention to quit. Therefore not eligible on the basis that
some participants wanted to quit
Pollak 2013 Did not provide follow-up of 6m or more
Prapavessis 2014 Did not provide follow-up of 6m or more
Prikryl 2014 Did not provide follow-up of 6m or more
Rennard 1990 Uncontrolled study. Nicotine gum used to assist smoking reduction. Outcomes were measures of
lower respiratory tract inflammation
Rennard 1994 Insufficient data available from conference abstract.
Rennard 2002 Short-term (8-wk) study of respiratory tract inflammation in smokers switching to potentially re-
duced exposure product (Eclipse)
Riggs 2001 Short-term (7-wk) cross-over pilot study of 2 reduction strategies combined with nicotine gum
Robinson 1984 Short-term (8-wk) trial comparing 'light' cigarettes to usual brand
Sarkar 2010 Short-term (8-day) study comparing biomarker exposure from continuing smoking, reduction and
ST use, ST use alone, and complete abstinence
Scherer 2006 Short-term (2-wk) cross-over study comparing conventional and charcoal filter cigarettes
Shi 2013 Did not provide follow-up of 6m or more
Shiffman 2009 Trial of nicotine gum for reduction as a precursor to cessation, amongst smokers attempting to
quit
Spain NNCG-008 Only short-term (4m) outcomes available from Pfizer summary. There was a stratification error
such that highly-dependent smokers received either nicotine 2 mg gum or placebo and the low-de-
pendent smokers received either nicotine 4 mg gum or placebo. Results were consistent with other
trials
Stein 2002 Short-term (3m) study comparing homocysteine levels in continuing smokers, reducers and quit-
ters
Strasser 2007 Laboratory study comparing CO exposure from smoking reduced nicotine cigarettes
Interventions to reduce harm from continued tobacco use (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
57
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study Reason for exclusion
Sun 2009 Trial of nicotine sublingual tablet for smoking cessation amongst people motivated to quit. Smok-
ing reduction was a secondary outcome
Tang 2013 Did not provide follow-up of 6m or more
Taylor 2014 Did not provide follow-up of 6m or more
Tuten 2012 Did not provide follow-up of 6m or more
Tønnesen 2005 Primary analysis was based on smoking status at end of study, not by allocation to cessation, re-
duction or continued smoking category. NRT was used to assist quitting or reduction and quit rates
at 4m were similar in cessation and reduction groups
Windsor 1999 Secondary analysis of 4 trials of cessation interventions for pregnant smokers. Rates of significant
reduction based on biochemical measures
Wu 2013 The intervention tested was a cessation intervention
ECHSS: electrically-heated cigarette smoking system.
CPD: cigarettes per day
M: month(s)
NRT: nicotine replacement therapy
ST: smokeless tobacco
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Smoking cessation and reduction in schizophrenia (SCARIS)
Methods Randomized controlled 3-arm trial with 12m follow-up investigating the efficacy and safety of EC in
schizophrenia patients
Setting: psychiatric and smoking cessation centres, Italy
Recruitment: local newspapers and radio/television advertisements
Participants 153 participants, schizophrenic in stable phase of illness, smoked at least 10 CPD over previous 5
years, aged 18 - 65, in good general health, not currently attempting to quit smoke or wishing to do
so in next 6m
Excluded if: use smokeless tobacco or NRT; pregnant or breastfeeding; current or recent (1 yr) his-
tory of drug or alcohol abuse; other significant comorbidities
Interventions 12-week supply of:
1. EC, high nicotine (24 mg)
2. EC, no nicotine (0 mg, with tobacco aroma)
3. Nicotine-free inhalator
Outcomes Follow-up visits at 4, 8, 12, 24 and 52 weeks
Outcome measures: Smoking cessation; smoking reduction (≥ 50% from baseline); adverse events;
quality of life; neurocognitive functioning; participant perceptions; satisfaction with products
Starting date September 2014
Caponetto 2014 
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Contact information Pasquale Caponetto; p.caponnetto@unict.it
Notes  
Caponetto 2014  (Continued)
 
 
Trial name or title Smoking cessation and reduction in depression (SCARID)
Methods 3-arm prospective 12m randomized controlled trial investigating efficacy and safety of ECs
Participants 129 participants
Inclusion criteria: diagnosis of major depressive disorder (MDD) (according to DSM-5 criteria),
smoke ≥ 10 CPD (for at least the past 5 years), age 18 - 65 years, in good general health, unwilling to
quit smoking in the next 30 days
Exclusion criteria: use of smokeless tobacco or NRT or other smoking cessation therapies, pregnan-
cy or breastfeeding, current or recent (< 1 yr) past history of alcohol or drug abuse or both, active
suicidal intention, other significant comorbidities according to the Investigator's clinical assess-
ment (e.g. cancer, acute myocardial infarction, unstable angina, severe cardiac arrhythmia, recent
cerebrovascular incident, or severe atherosclerosis)
Interventions 12-week supply of:
1. EC 24 mg nicotine
2. EC 0 mg nicotine
3. Nicotine-free inhalator
Outcomes Follow-up visits at 4, 8, 12, 24 and 52 wks
Outcome measures:
Smoking cessation
Smoking reduction (≥ 50% from baseline)
Adverse events
Quality of life
Neurocognitive functioning
Participant perceptions and satisfactions with products
Starting date February 2015
Contact information Pasquale Caponnetto; p.caponnetto@unict.it
Notes  
NCT02124187 
 
 
Trial name or title Nicotine-assisted reduction to stop in pharmacies - the redpharm study
Taskila 2012 
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Methods 2 × 2 randomized factorial trial of behavioural support versus no support and short versus standard
length reduction programme
Participants Pharmacists asked to recruit participants opportunistically as well as receiving referrals from GPs
Estimated sample size of 160 participants recruited in 10 pharmacies
Participants must be:
1. Aged 18 years or older.
2. Daily smokers with either a CO of at least 10 ppm at least 15 mins after last smoking or smoke at
least 10 cigarettes or 8 g of loose tobacco as "roll up" cigarettes daily
3. Do not intend to stop in the next month, but are prepared to reduce their consumption with any
of the programmes offered
4. Evidence of a personally signed and dated informed consent document indicating that the par-
ticipant has been informed of all pertinent aspects of the study and consents to participate and
be randomized to either arm
5. Have either a telephone or email for follow-up
Participants presenting any of the following are excluded:
1. Currently using other NRT, bupropion, nortriptyline, mecamylamine, reserpine, or varenicline, or
undergoing any treatment for tobacco dependence (e.g. acupuncture) that they are not willing
to stop using
2. Unstable angina pectoris, myocardial infarction, acute coronary syndrome, or cerebrovascular
accident during the last 3 weeks
3. Severe cardiac arrhythmia
4. Currently uncontrolled hyperthyroidism
5. Active phaeocromocytoma
6. Pregnancy, lactation or intended pregnancy in the coming year
7. A severe acute or chronic medical or psychiatric condition or previously diagnosed clinically im-
portant renal or hepatic disease, that may increase the risk associated with study participation or
may interfere with the interpretation of study results and, in the judgement of the investigator,
would make the potential participant inappropriate for entry into this study
Interventions Trial arms:
1. Short with behavioural support for smoking reduction (4 weeks)
2. Standard with behavioural support for smoking reduction (34 weeks)
3. Short with leaflet providing advice on smoking reduction (4 weeks)
4. Standard with leaflet providing advice on smoking reduction (34 weeks)
Use of NRT encouraged in all trial arms
Outcomes % of those who reduce and sustain their consumption to at least 50% of baseline value, the propor-
tion of people who attain 4-week and 6m abstinence
Starting date 2010
Contact information Paul Aveyard; paul.aveyard@phc.ox.ac.uk
Notes  
Taskila 2012  (Continued)
CPD: cigarettes a day
EC: electronic cigarette
NRT: nicotine replacement therapy
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Comparison 1.   Nicotine replacement therapy to assist smoking reduction versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Reduction in cigarettes/day of > 50%
of baseline or cessation
8 3081 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.44, 2.13]
1.1 Choice of NRT type versus placebo 2 848 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.11, 1.75]
1.2 Nicotine gum versus placebo 4 1404 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [1.57, 4.00]
1.3 Nicotine inhaler versus placebo 2 829 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [1.70, 6.77]
2 Cessation at long-term follow-up
(subgroups by type of NRT)
8 3081 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [1.43, 2.44]
2.1 Choice of NRT type versus placebo 2 848 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [1.04, 2.33]
2.2 Nicotine gum versus placebo 4 1404 Risk Ratio (M-H, Fixed, 95% CI) 2.38 [1.46, 3.89]
2.3 Nicotine inhaler versus placebo 2 829 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [1.13, 3.20]
3 Other outcomes - consumption
markers
    Other data No numeric data
4 Other outcomes - health markers     Other data No numeric data
 
 
Analysis 1.1.   Comparison 1 Nicotine replacement therapy to assist smoking reduction
versus placebo, Outcome 1 Reduction in cigarettes/day of > 50% of baseline or cessation.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.1 Choice of NRT type versus placebo  
Kralikova 2009 75/209 28/105 28.91% 1.35[0.93,1.94]
Etter 2004 83/265 59/269 45.42% 1.43[1.07,1.9]
Subtotal (95% CI) 474 374 74.33% 1.4[1.11,1.75]
Total events: 158 (Treatment), 87 (Control)  
Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.8); I2=0%  
Test for overall effect: Z=2.89(P=0)  
   
1.1.2 Nicotine gum versus placebo  
Australia NNCG-017 13/218 9/218 6.98% 1.44[0.63,3.31]
Haustein 2003 17/97 8/96 6.24% 2.1[0.95,4.64]
Batra 2005 15/184 5/180 3.92% 2.93[1.09,7.91]
Wennike 2003 13/205 1/206 0.77% 13.06[1.72,98.94]
Subtotal (95% CI) 704 700 17.91% 2.5[1.57,4]
Total events: 58 (Treatment), 23 (Control)  
Heterogeneity: Tau2=0; Chi2=4.53, df=3(P=0.21); I2=33.79%  
Test for overall effect: Z=3.84(P=0)  
Favours placebo 1000.01 100.1 1 Favours NRT
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
1.1.3 Nicotine inhaler versus placebo  
Bolliger 2000 19/200 6/200 4.65% 3.17[1.29,7.76]
Rennard 2006 15/215 4/214 3.11% 3.73[1.26,11.06]
Subtotal (95% CI) 415 414 7.76% 3.39[1.7,6.77]
Total events: 34 (Treatment), 10 (Control)  
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%  
Test for overall effect: Z=3.46(P=0)  
   
Total (95% CI) 1593 1488 100% 1.75[1.44,2.13]
Total events: 250 (Treatment), 120 (Control)  
Heterogeneity: Tau2=0; Chi2=12.69, df=7(P=0.08); I2=44.85%  
Test for overall effect: Z=5.61(P<0.0001)  
Test for subgroup differences: Chi2=9.32, df=1 (P=0.01), I2=78.53%  
Favours placebo 1000.01 100.1 1 Favours NRT
 
 
Analysis 1.2.   Comparison 1 Nicotine replacement therapy to assist smoking reduction
versus placebo, Outcome 2 Cessation at long-term follow-up (subgroups by type of NRT).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.2.1 Choice of NRT type versus placebo  
Etter 2004 31/265 25/269 31.66% 1.26[0.76,2.07]
Kralikova 2009 39/209 9/105 15.29% 2.18[1.1,4.32]
Subtotal (95% CI) 474 374 46.95% 1.56[1.04,2.33]
Total events: 70 (Treatment), 34 (Control)  
Heterogeneity: Tau2=0; Chi2=1.62, df=1(P=0.2); I2=38.14%  
Test for overall effect: Z=2.16(P=0.03)  
   
1.2.2 Nicotine gum versus placebo  
Australia NNCG-017 10/218 7/218 8.93% 1.43[0.55,3.68]
Wennike 2003 19/205 7/206 8.91% 2.73[1.17,6.35]
Batra 2005 20/184 7/180 9.03% 2.8[1.21,6.45]
Haustein 2003 2/97 0/96 0.64% 4.95[0.24,101.75]
Subtotal (95% CI) 704 700 27.52% 2.38[1.46,3.89]
Total events: 51 (Treatment), 21 (Control)  
Heterogeneity: Tau2=0; Chi2=1.58, df=3(P=0.66); I2=0%  
Test for overall effect: Z=3.46(P=0)  
   
1.2.3 Nicotine inhaler versus placebo  
Bolliger 2000 21/200 17/200 21.69% 1.24[0.67,2.27]
Rennard 2006 17/215 3/214 3.84% 5.64[1.68,18.97]
Subtotal (95% CI) 415 414 25.53% 1.9[1.13,3.2]
Total events: 38 (Treatment), 20 (Control)  
Heterogeneity: Tau2=0; Chi2=5.01, df=1(P=0.03); I2=80.04%  
Test for overall effect: Z=2.4(P=0.02)  
   
Total (95% CI) 1593 1488 100% 1.87[1.43,2.44]
Total events: 159 (Treatment), 75 (Control)  
Favours placebo 1000.01 100.1 1 Favours NRT
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Tau2=0; Chi2=9.94, df=7(P=0.19); I2=29.58%  
Test for overall effect: Z=4.61(P<0.0001)  
Test for subgroup differences: Chi2=1.72, df=1 (P=0.42), I2=0%  
Favours placebo 1000.01 100.1 1 Favours NRT
 
 
Analysis 1.3.   Comparison 1 Nicotine replacement therapy to assist smoking
reduction versus placebo, Outcome 3 Other outcomes - consumption markers.
Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
Australia NNCG-017 Not reported Not reported At 12m reductions from base-
line of > 50% as verified by re-
duction in CO
Nicotine gum group 3/218
(1.4%); placebo group 2/218
(0.9%) (NS)
-
Batra 2005 At 13m % reductions from
baseline for attenders includ-
ing quitters: (n, mean, SD)
CPD active 55, 64.0% (33.1%);
placebo 39, 51.0% (33.9%) (NS)
As for CPD/CO based on atten-
ders with data, including quit-
ters
Cotinine % reduction active n
= 52, 31.8% (44.2%), placebo
36, 25.5% (40.0%) (P = 0.04)
Thiocyanate active 46, 20.5%
(30.5%), placebo 33, 16.7%
(22.8%) (NS)
At 13m % reductions from
baseline for attenders includ-
ing quitters: (n, mean, SD)
CO active 55, 43.1% (39.3%);
placebo 39, 27.1% (40.5%)
Sustained CO reduction > 20%
at 13m; active 13.6%, placebo
5.6%
-
Bolliger 2000 As % of baseline value report-
ed for participants still using
inhalers every day at 18m: (n,
mean, SD)
Intervention 22, 36.2%
(29.6%); placebo 8, 67.2%
(27.8%) (P = 0.02)
Among successful reducers (n
= 25; 19 intervention, 6 con-
trol), mean (SD) CPD at 24m:
5.0 (6.4), entire placebo group
18.2 (11.2)
Among successful reducers (n
= 25; 19 intervention, 6 con-
trol), mean (SD) cotinine (ng/
ml) at 24m: 139 (167), entire
placebo group 325 (163) (P <
0.05)
As % of baseline value report-
ed for participants still using
inhalers every day at 18m: (n,
mean, SD)
Intervention 22, 71.0%
(58.8%); placebo 8, 81.7%
(41.1%) (NS)
Among successful reducers (n
= 25; 19 intervention, 6 con-
trol), mean (SD) CO (ppm) at
24m: successful reducers 10.0
(8.5), entire placebo group 20.6
(11.2)
-
Etter 2004 After 26m the mean absolute
reduction (ITT) in CPD was 9.8
for nicotine, 7.7 for placebo &
control. Median reduction 7.5
vs 5.0.
Amongst participants followed
up at 60 months (excl quitters)
the mean absolute reduction
in CPD ranged from 6.3 to 7.9
(NS between groups). CPD as
% of baseline was 74% NRT,
80% placebo & no treatment
Not reported Not reported -
Hanson 2008 Mean CPD at baseline; end of
treatment; 3m; 6m:
Nicotine patch: 11.1; 5.0; 6.1;
8.9
Nicotine gum: 12.7; 6.0; 7.6; 9.3
Placebo: 11.6; 5.4; 4.6; 7.8
Reduction in all groups from
baseline (P < 0.0001) but differ-
ence between groups not sta-
tistically significant
Mean cotinine (ng/ml) at base-
line; end of treatment; 3m; 6m:
Nicotine patch: 3476; 3464;
3264; 4660
Nicotine gum: 3759; 3946;
2718; 4346
Placebo: 3072; 2505; 2734;
3949
Difference between groups not
statistically significant
Mean CO (ppm) at baseline;
end of treatment; 3m; 6m:
Nicotine patch: 7.1; 5.2; 7.6; 8.7
Nicotine gum: 6.9; 6.7; 7.9; 9.1
Placebo: 5.7; 5.1; 5.4; 6.0
Significant interaction be-
tween treatment group and
follow-up visit reported, with
higher CO in nicotine gum than
nicotine patch group in third
week of follow-up (P = 0.05).
Mean total NNAL (pmol/mg) at
baseline; end of treatment:
Nicotine patch: 0.66; 0.65
Nicotine gum: 0.79; 0.87
Placebo: 0.54; 0.76
Difference between groups not
statistically significant
Haustein 2003 CPD not reported as a continu-
ous variable
Between-study group differ-
ences are not supplied. Com-
parisons were made between
reducers (50%+ CPD) and non-
reducers (< 50% CPD), and
reducers had a significant-
Between-study group differ-
ences are not supplied.
Measures of CO reduction gen-
erally matched levels of CPD
reduction i.e. those partici-
pants who reduced CPD by
-
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Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
ly greater reduction in plas-
ma cotinine and plasma thio-
cyanate between baseline and
12m follow-up reducers and
non-reducers experienced a
significant reduction in plas-
ma cotinine, whereas only re-
ducers experienced a signifi-
cant reduction in plasma thio-
cyanate)
50% - 74% reduced their CO
by a mean of 51%, those who
reduced CPD by 25% - 49% re-
duced their CO by a mean of
32.6% and those who reduced
CPD by 0% - 24% reduced their
CO by a mean of 25.4%
Kralikova 2009 Not reported Significant reduction in plas-
ma cotinine in abstainers at
4m and 12m, and in reducers
at 4m (mean at 12m: abstain-
ers 40ng/mL, reducers 216,
failures 271)
Significant reduction in CO
in abstainers and reducers at
4m and 12m, and in failures
at 12m, with larger reduction
from baseline in abstainers
and reducers (mean at 12m:
abstainers 2.7 ppm, reducers
11.7, failures 17.2)
-
Rennard 2006 Amongst successful reducers
at 4m (reduction in daily smok-
ing of at least 50% from base-
line) the reduction in average
CPD was 74% in both active
(mean dropped from 29.1 to
7.6) and placebo (31.9 to 8.1)
groups. In all participants, re-
duction in average CPD at 24m
was 14.6% in active group and
12.2% in placebo group
Reduction from baseline in co-
tinine and thiocyanate in both
active and placebo groups.
Levels fell by more in ≥ 50%
reducers at 4 months than in
non-reducers
Amongst sustained reducers
at 15m, reducers of 50% to <
75% reduced their average CO
by 8.3 ppm. Reducers of > 75%
(incl quitters) reduced average
CO by 25.2 ppm
No differences across treat-
ment groups in any markers.
Exploratory analyses of suc-
cessful reducers at 4m showed
significant change from base-
line in HDL but no other mark-
ers
Wennike 2003 At 24m based on remaining
participants no differences be-
tween active and placebo. CPD
54% vs 61% of baseline (P =
0.2). At 4m effect size was sim-
ilar (56% vs 67%) and statisti-
cally significant (P = 0.03)
At 24m based on remaining
participants no differences be-
tween active and placebo.
Cotinine 83% vs 93% of base-
line (P = 0.1), thiocyanate 74%
vs 82% (P = 0.2). At 4m differ-
ences were statistically signifi-
cant, with the direction of the
effect reversed for cotinine
(cotinine 98% vs 86%, P = 0.01;
thiocyanate 79% vs 89%, P <
0.001)
At 24m based on remaining
participants no differences be-
tween active and placebo. CO
63% vs 76% of baseline (P =
0.1). At 4m effect size was sim-
ilar (71% vs 84%) and statisti-
cally significant (P = 0.01)
-
 
 
Analysis 1.4.   Comparison 1 Nicotine replacement therapy to assist smoking
reduction versus placebo, Outcome 4 Other outcomes - health markers.
Other outcomes - health markers
Study Lipoproteins Haematolog-
ical markers
Pulmonary function Quality of life Other health markers
Batra 2005 Not reported No statistically signifi-
cant change in any car-
diovascular risk markers
(WBC, fibrinogen, CRP)
between baseline and
month 12 in the 20 suc-
cessful sustained reduc-
ers/abstainers
Not reported Not reported Not reported
Bolliger 2000 Comparison between
25 (19 active, 6 place-
bo) sustained reducers
and 285 non-reducers at
24m. Both groups had
statistically significant
reduction from baseline
in total cholesterol/HDL
ratio and LDL and in-
crease from baseline in
HDL. Placebo group also
had statistically signifi-
cant reduction in total
cholesterol. Difference
Comparison between
25 (19 active, 6 place-
bo) sustained reduc-
ers and 285 non-reduc-
ers at 24m. Both groups
had statistically signif-
icant reduction from
baseline in haemoglobin
and haematocrit. Place-
bo group also had sta-
tistically significant in-
crease in fibrinogen and
WBC. Difference between
groups statistically sig-
Comparison between
25 (19 active, 6 place-
bo) sustained reduc-
ers and 285 non-reduc-
ers at 24m. Both groups
had statistically signif-
icant reduction from
baseline in FEV1 but not
FVC. Difference between
groups statistically sig-
nificant only for FEV1,
with greater reduction in
reducers
Comparison between
25 (19 active, 6 place-
bo) sustained reducers
and 285 non-reducers at
24m. Both groups had
statistically significant
increase from baseline
in general health, physi-
cal functioning and emo-
tional well-being. Place-
bo group additionally
had statistically signif-
icant increase in ener-
gy. Difference between
Comparison between
25 (19 active, 6 place-
bo) sustained reduc-
ers and 285 non-reduc-
ers at 24m. Both groups
had statistically signif-
icant reduction from
baseline for SBP but
not pulse rate or DBP.
Weight increased in fe-
male reducers and in
both sexes in placebo
group. Difference be-
tween groups statisti-
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Other outcomes - health markers
Study Lipoproteins Haematolog-
ical markers
Pulmonary function Quality of life Other health markers
between groups statisti-
cally significant only for
total cholesterol/HDL ra-
tio, with greater reduc-
tion in reducers
nificant only for haemo-
globin, with greater re-
duction in reducers
groups statistically sig-
nificant only for general
health, with greater in-
crease in reducers
cally significant only for
pulse rate (greater reduc-
tion in reducers) and fe-
male weight (greater in-
crease in reducers)
Etter 2004 Not reported Not reported Not reported Not reported Average weight gain
across all 3 groups over
60m was 2.4 kg (no sig-
nificant difference be-
tween groups). Greater
weight gain for success-
ful quitters than for
smokers was observed
for men (mean 6 kg vs 2.2
kg) but not for women
(mean 2.8 kg vs 2.1 kg)
Haustein 2003 In those participants
who successfully re-
duced their smoking
by 50% or more there
was a 0.75% increase
in HDL(-0.41 mg/dL
change, N = 23), a 6.3%
decrease in LDL (-8.30
mg/dL change, N = 22),
a 4.2% decrease in cho-
lesterol and a 28.2% in-
creases in triglycerides
between baseline and
12m follow-up. For the
cholesterol and triglyc-
eride measures a com-
parison was also made
between reducers and
non-reducers and there
was no between-group
significant differences
in the changes found be-
tween baseline and 12m
follow-up
In those participants
who successfully re-
duced their smoking by
50% or more there was a
10.3% decrease in WBC
(-0.85 109/L change, N
= 24), a 10.4% decrease
in fibrinogen (-35.1 mg/
dL change, N = 24) and
42.6% decrease in CRP
(-0.26 mg/dL change, N
= 24) between baseline
and 12m follow-up.
There was a 4.1% re-
duction in RBC, a 1.9%
reduction in platelets,
and a 4.5% decrease in
haemoglobin. On these
measures a comparison
was made between re-
ducers and non-reduc-
ers and there was no
between-group signifi-
cant differences in the
changes found between
baseline and 12m fol-
low-up
Not reported In those participants
who had reduced their
smoking by 50%+ at
12m significant improve-
ments were observed in
10 of 14 QOL items on
a rating scale (anxiety,
cognitive function, emo-
tional well-being, ener-
gy, general health, pain,
physical functioning, self
control, social interac-
tion, worry)
After 12m the mean SBP,
DBP and pulse rate were
unchanged in both re-
ducers and non-reducers
compared to baseline.
At 1 year the 24 success-
ful reducers (50%+) had
gained a mean of 3.49
kg compared to a mean
weight gain of 1.14 kg
in the non-reducers (P =
0.019)
Kralikova 2009 Not reported No significant changes in
WBC amongst reducers
Not reported Not reported Not reported
Rennard 2006 Reducers at 4m had a
statistically significant
increase from baseline in
HDL (mean change 2.11
mg/dl, P = 0.003) and de-
crease in WBC (-0.34 ×
109/l, P = 0.03). No sig-
nificant change in LDL
(-5.76 mg/dl, P = 0.23)
Reducers at 4m had
a statistically signif-
icant decrease from
baseline in CRP (mean
change -0.09 mg/dl, P =
0.04) and no significant
change in fibrinogen
(-18.6 mg/dl, P = 0.15)
Not reported Greatest improvements
in cough, phlegm, short-
ness of breath, and sens-
es of smell and taste
were observed in those
who reduced consump-
tion by ≥ 50% from base-
line. These participants
also reported signifi-
cantly greater improve-
ments in self-control (P
< 0.001), with no differ-
ence in other quality of
life outcomes
Average weight gain
among 20 participants
who had quit smoking at
15m was 5.0 kg (P < 0.001
compared to those who
did not quit, for whom
there was no significant
weight change)
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Comparison 2.   NRT combined with counselling to assist smoking reduction versus brief cessation advice
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Reduction in cigarettes/day of > 50% of
baseline or cessation
2 1306 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.26, 2.43]
1.1 Nicotine gum, or patch, combined with
counselling
2 1306 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.26, 2.43]
2 Cessation at long-term follow-up 2 1306 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.89, 2.50]
2.1 Nicotine gum, or patch, combined with
counselling
2 1306 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.89, 2.50]
3 Other outcomes - consumption markers     Other data No numeric data
4 Other outcomes - health markers     Other data No numeric data
 
 
Analysis 2.1.   Comparison 2 NRT combined with counselling to assist smoking reduction versus
brief cessation advice, Outcome 1 Reduction in cigarettes/day of > 50% of baseline or cessation.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.1.1 Nicotine gum, or patch, combined with counselling  
Chan 2011 178/928 22/226 65.7% 1.97[1.3,2.99]
Joseph 2008 25/78 18/74 34.3% 1.32[0.79,2.21]
Subtotal (95% CI) 1006 300 100% 1.75[1.26,2.43]
Total events: 203 (Treatment), 40 (Control)  
Heterogeneity: Tau2=0; Chi2=1.47, df=1(P=0.23); I2=31.8%  
Test for overall effect: Z=3.31(P=0)  
   
Total (95% CI) 1006 300 100% 1.75[1.26,2.43]
Total events: 203 (Treatment), 40 (Control)  
Heterogeneity: Tau2=0; Chi2=1.47, df=1(P=0.23); I2=31.8%  
Test for overall effect: Z=3.31(P=0)  
Favours brief advice 100.1 50.2 20.5 1 Favours NRT+counselling
 
 
Analysis 2.2.   Comparison 2 NRT combined with counselling to assist smoking
reduction versus brief cessation advice, Outcome 2 Cessation at long-term follow-up.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.2.1 Nicotine gum, or patch, combined with counselling  
Chan 2011 74/928 10/226 63.52% 1.8[0.95,3.43]
Joseph 2008 9/78 9/74 36.48% 0.95[0.4,2.26]
Subtotal (95% CI) 1006 300 100% 1.49[0.89,2.5]
Total events: 83 (Treatment), 19 (Control)  
Favours brief advice 100.1 50.2 20.5 1 Favours NRT+counselling
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Tau2=0; Chi2=1.38, df=1(P=0.24); I2=27.32%  
Test for overall effect: Z=1.52(P=0.13)  
   
Total (95% CI) 1006 300 100% 1.49[0.89,2.5]
Total events: 83 (Treatment), 19 (Control)  
Heterogeneity: Tau2=0; Chi2=1.38, df=1(P=0.24); I2=27.32%  
Test for overall effect: Z=1.52(P=0.13)  
Favours brief advice 100.1 50.2 20.5 1 Favours NRT+counselling
 
 
Analysis 2.3.   Comparison 2 NRT combined with counselling to assist smoking reduction
versus brief cessation advice, Outcome 3 Other outcomes - consumption markers.
Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
Chan 2011 Among non-quitters, CPD at
6m was significantly lower in
the combined intervention
group (mean (SD) 9.5 (8.4))
than in the control group (13.1
(9.3)) (P < 0.001)
Urinary cotinine only report-
ed as a validation measure for
self-reported quitters
Difference in CO at 6m not sta-
tistically significant (mean (SD)
7.6 (9.3) in combined interven-
tion group, 5.2 (10.7) in control
group, P = 0.30)
-
Joseph 2008 Reductions in CPD similar in
both groups; decreasing from
˜27 CPD at baseline to ˜18
CPD at 18m, but with consid-
erable variation between indi-
viduals
Urinary cotinine: no significant
difference between groups in
reduction from baseline
CO (ppm) reduction in both
groups (Smoking reduction
group mean 24 (baseline) to 16
(18m); Usual care group mean
25 (baseline) to 18 (18m)),
no significant difference (P =
0.155)
Change from baseline in nico-
tine, total NNAL and 1-OHP
was similar in both treatment
groups
 
 
Analysis 2.4.   Comparison 2 NRT combined with counselling to assist smoking
reduction versus brief cessation advice, Outcome 4 Other outcomes - health markers.
Other outcomes - health markers
Study Lipoproteins Haematolog-
ical markers
Pulmonary function Quality of life Other health markers
Joseph 2008 Not reported Markers of inflammation
and oxidation including
WBC count, hs-CRP and
F2-isoprostanes showed
minimal change from
baseline or between
groups. Change from
baseline in fibrinogen
differed between groups
(P = 0.019) but effect size
was small (Smoking re-
duction group: mean 383
mg/dL at baseline, 367 at
18m; Usual care group:
384 at baseline, 352 at
18m)
Not reported No differences between
groups in quality of life
at any time point
No differences between
groups in frequency of
angina at any time point
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Comparison 3.   Nicotine patches versus placebo for temporary abstinence
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Cessation at long-term follow-up 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 3.1.   Comparison 3 Nicotine patches versus placebo for
temporary abstinence, Outcome 1 Cessation at long-term follow-up.
Study or subgroup Patch Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Nackaerts 2009 44/150 41/146 1.04[0.73,1.5]
Favours placebo 1000.01 100.1 1 Favours patches
 
 
Comparison 4.   Bupropion to assist smoking reduction versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Outcomes at long-term follow-up 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Cessation 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Reduction in cigarettes/day of > 50%
of baseline or cessation
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Other outcomes - consumption mark-
ers
    Other data No numeric data
 
 
Analysis 4.1.   Comparison 4 Bupropion to assist smoking reduction
versus placebo, Outcome 1 Outcomes at long-term follow-up.
Study or subgroup Treatment Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
4.1.1 Cessation  
Hatsukami 2004a 20/295 16/299 1.27[0.67,2.4]
   
4.1.2 Reduction in cigarettes/day of > 50% of baseline or cessation  
Hatsukami 2004a 28/295 28/299 1.01[0.62,1.67]
Favours placebo 100.1 50.2 20.5 1 Favours bupropion
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Analysis 4.2.   Comparison 4 Bupropion to assist smoking reduction
versus placebo, Outcome 2 Other outcomes - consumption markers.
Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
Hatsukami 2004a Reduction in mean CPD from
baseline to 3m: Bupropion
group 6.5, placebo group 6.3.
Proportion with 50% reduction
in CPD from baseline statisti-
cally significant at 6m (16%
vs 9%, P = 0.02) but not at 3m
(28% vs 17%, P = 0.41) or 12m
(5% vs 7%, P = 0.55)
In ITT analysis, mean urinary
cotinine decrease from base-
line greater in bupropion
group than in placebo group
(mean decrease approximate-
ly 340 ng/ml vs 130 ng/ml,
P = 0.008) but difference at
12m not statistically signifi-
cant (mean decrease 82 ng/
mL vs 28 ng/ml, P = 0.25). Sim-
ilar conclusion for % of partici-
pants achieving 50% reduction
in urine cotinine
Not reported -
 
 
Comparison 5.   Varenicline to assist smoking reduction versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Outcomes at long-term follow-up 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Cessation 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Other outcomes - consumption
markers
    Other data No numeric data
 
 
Analysis 5.1.   Comparison 5 Varenicline to assist smoking reduction
versus placebo, Outcome 1 Outcomes at long-term follow-up.
Study or subgroup Treatment Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
5.1.1 Cessation  
Hughes 2011 15/107 8/111 1.95[0.86,4.4]
Favours placebo 100.1 50.2 20.5 1 Favours varenicline
 
 
Analysis 5.2.   Comparison 5 Varenicline to assist smoking reduction
versus placebo, Outcome 2 Other outcomes - consumption markers.
Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
Hughes 2011 Reduction in CPD was high-
er in varenicline group than
in control group (reduction
from baseline 5.8 (29%) vs 3.2
(17%), P = 0.003)
Not reported Not reported -
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Comparison 6.   Ecigarettes to assist smoking reduction versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Outcomes at long-term follow-up 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Reduction in cigarettes/day of > 50%
of baseline or cessation
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Cessation 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Other outcomes - consumption markers     Other data No numeric data
3 Other outcomes - health markers     Other data No numeric data
 
 
Analysis 6.1.   Comparison 6 Ecigarettes to assist smoking reduction
versus placebo, Outcome 1 Outcomes at long-term follow-up.
Study or subgroup Treatment Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
6.1.1 Reduction in cigarettes/day of > 50% of baseline or cessation  
Caponnetto 2013 41/200 16/100 1.28[0.76,2.17]
   
6.1.2 Cessation  
Caponnetto 2013 22/200 4/100 2.75[0.97,7.76]
Favours placebo 100.1 50.2 20.5 1 Favours ecigs
 
 
Analysis 6.2.   Comparison 6 Ecigarettes to assist smoking reduction
versus placebo, Outcome 2 Other outcomes - consumption markers.
Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
Caponnetto 2013 Significant differences in CPD
between groups (with higher
CPD in the no-nicotine group)
were reported at 2, 6 and 8
wks, but not at other interme-
diate time points, nor at the
end of the study (52 wks, medi-
an CPD 12 - 14 in all groups)
Saliva cotinine levels at wk 6
and wk 12 were near zero in
the no-nicotine group, and
not significantly different be-
tween the other 2 study groups
(median (ng/ml) 42.5 (wk 6)
and 91.0 (wk 12) in the 7.2 mg
nicotine group; 67.8 (wk 6) and
69.8 (wk 12) in the 5.4 mg nico-
tine group)
Significant difference in CO be-
tween groups was reported
at wk 6 (P = 0.01) but at none
of the other 7 time points dur-
ing follow-up (at 52 wks, me-
dian CO was 15 - 17 ppm in all
groups)
-
 
 
Analysis 6.3.   Comparison 6 Ecigarettes to assist smoking reduction
versus placebo, Outcome 3 Other outcomes - health markers.
Other outcomes - health markers
Study Lipoproteins Haematolog-
ical markers
Pulmonary function Quality of life Other health markers
Caponnetto 2013 Not reported Not reported No significant changes
in resting heart rate, SBP
Not reported No significant changes in
weight over time or be-
tween groups
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Other outcomes - health markers
Study Lipoproteins Haematolog-
ical markers
Pulmonary function Quality of life Other health markers
or DBP over time or be-
tween groups
 
 
Comparison 7.   Snus to reduce and replace smoking versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Outcomes at long-term follow-up 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Reduction in cigarettes/day of > 50%
of baseline or cessation
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Cessation 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Other outcomes - consumption markers     Other data No numeric data
3 Other outcomes - health markers     Other data No numeric data
 
 
Analysis 7.1.   Comparison 7 Snus to reduce and replace smoking
versus placebo, Outcome 1 Outcomes at long-term follow-up.
Study or subgroup Treatment Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
7.1.1 Reduction in cigarettes/day of > 50% of baseline or cessation  
Joksić 2011 101/158 109/161 0.94[0.81,1.11]
   
7.1.2 Cessation  
Joksić 2011 9/158 3/161 3.06[0.84,11.08]
Favours placebo 100.1 50.2 20.5 1 Favours snus
 
 
Analysis 7.2.   Comparison 7 Snus to reduce and replace smoking
versus placebo, Outcome 2 Other outcomes - consumption markers.
Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
Joksić 2011 At 48 wks, CPD had decreased
to around ⅓ of baseline in
each group (mean 7.6 (snus
group), 8.6 (placebo group)),
difference between groups not
statistically significant
Reduction from baseline in
plasma cotinine was similar
in both groups (snus group:
mean 98.9 ng/ml (baseline),
66.1 (48 wks); placebo group:
101.2 (baseline), 69.1 (48 wks))
Reduction from baseline in ex-
haled CO was similar in both
groups (snus group: mean 23.5
ppm (baseline), 11.5 (48 wks);
placebo group: 23.5 (baseline),
12.1 (48 wks))
-
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Analysis 7.3.   Comparison 7 Snus to reduce and replace smoking
versus placebo, Outcome 3 Other outcomes - health markers.
Other outcomes - health markers
Study Lipoproteins Haematolog-
ical markers
Pulmonary function Quality of life Other health markers
Joksić 2011 No changes in total, LDL
or HDL cholesterol over
time or differences be-
tween groups.
No changes in WBC, CRP
or fibrinogen over time
or differences between
groups.
No changes in FEV1.0,
FVC or FEV% over time
or differences between
groups.
Not reported No changes in SBP, DBP,
weight or BMI over time
or differences between
groups.
 
 
Comparison 8.   PREPs to assist smoking reduction versus smoking as usual
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Other outcomes - consumption markers     Other data No numeric data
2 Cessation at long-term follow-up 1   Risk Ratio (M-H, Fixed, 95%
CI)
Totals not selected
3 Other outcomes - health markers     Other data No numeric data
 
 
Analysis 8.1.   Comparison 8 PREPs to assist smoking reduction versus
smoking as usual, Outcome 1 Other outcomes - consumption markers.
Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
Benowitz 2012 Small but statistically signif-
icant differences between
control and reduced-nico-
tine groups in change in CPD
from baseline to 26 wks, and
from 14 wks to 26 wks (mean
CPD: control 19 (baseline),
21 (14 wks), 22 (26 wks); re-
duced-nicotine 22 (baseline),
24 (14 wks), 20 (26 wks))
For plasma cotinine, larger re-
ductions from baseline to 14
wks and 26 wks follow-up in
reduced-nicotine group (mean
(ng/ml) 256 (baseline), 240 (26
wks)) than in control group
(mean 256 (baseline), 113 (26
wks)) (P < 0.001), with greatest
decline in the reduced-nico-
tine group occurring between
6 and 18 wks
No differences between
groups at any time point
(mean CO (ppm): control 20
(baseline), 24 (14 wks), 20 (26
wks); reduced-nicotine 21
(baseline), 25 (14 wks), 23 (26
wks))
Pattern of plasma nicotine
was similar to that seen for co-
tinine (greater decline in re-
duced-nicotine group than
in control group). Signifi-
cantly greater reduction be-
tween 14 wks and 26 wks in
reduced-nicotine group than
in control group. No differ-
ence between groups in sum
of phens, 2-naphthol, sum of
fluors or 1-hydroxypyrene
Mendes 2008 Mean CPD at baseline; short-
term phase; long-term phase:
MFF group: 19.7; "between
19.1 and 19.7"; 26.3
ML group: 20.3; "between 20.0
and 20.5"; 26.8
MUL group: 19.8; "between
18.6 and 19.8"; 30.3
Statistically significantly low-
er during the short-term phase
in MUL group (mean 230 ng/
mL) than in MFF group. No dif-
ference between ML group and
MFF group
Not reported Mean urine nicotine equiv-
alents over the whole study
was lower in MUL group (mean
13.1 mg/24 hrs) in MFF group
(16.8) (P = 0.02) but similar
between MFF group and ML
group (15.4) (P = 0.76). A sim-
ilar pattern was observed in
the short-term phase (first 8
days), when levels were slight-
ly higher in all groups. Overall
urine total NNAL was lower in
MUL group than in MFF group
in the short-term phase (P =
0.05); differences in long-term
phase not significant. Urine to-
tal 1-OHP lower in MUL group
than in MFF group during both
phases. Urine mutagenicity:
differences between groups
not significant. COHb tended
to be lowest in MUL group and
highest in ML group. Some ev-
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Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
idence that urine S-PMA was
lower in MUL group than MFF
group in long-term phase (P
= 0.05). 3-HPMA decreased
from baseline in all groups.
Mean values of the Fagerström
Test for Nicotine Dependence
"were between 5.4 and 5.8
on a scale of 0–9 and did not
change during the study".
Roethig 2008 Mean CPD increased from 24.3
(baseline) to 63.4 (52 wks) in
EHCSS group (a 95% increase)
and from 23.3 (baseline) to
36.6 in CC group (a 27% in-
crease) (P < 0.001 for differ-
ence between groups)
Over 12m, mean plasma co-
tinine decreased by 16% in
EHCSS group and increased by
5% in CC group (P = 0.018)
Not reported Over 12m, urine nicotine
equivalents decreased by
18% in EHCSS group and in-
creased by 0.1% in CC group (P
= 0.014). Also greater and sta-
tistically significant reductions
in the EHCSS group than in the
CC group in total NNAL, total
1-OHP, urine mutagenicity, 4-
ABP Hb adducts, COHb AUC(7
- 23 hrs) and 3-HPMA (all P <
0.001)
Sarkar 2008 In different study groups,
mean CPD was between 17.5
and 19.1 at baseline and in-
creased to between 24.6 and
35.1 at 24 wks (differences be-
tween groups not statistically
significant)
Not reported Not reported For most time points in both
short- and long-term fol-
low-up, MHBMA, 3-HPMA and
S-PMA were all statistically sig-
nificantly lower in the test cig-
arette groups than in the con-
ventional cigarette groups. At
most follow-up times, differ-
ences between groups in nico-
tine equivalents, total NNAL,
total 1-OHP were not statisti-
cally significant
 
 
Analysis 8.2.   Comparison 8 PREPs to assist smoking reduction versus
smoking as usual, Outcome 2 Cessation at long-term follow-up.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Benowitz 2012 2/80 1/55 1.38[0.13,14.79]
Favours smoking as usual 1000.01 100.1 1 Favours PREPs
 
 
Analysis 8.3.   Comparison 8 PREPs to assist smoking reduction versus
smoking as usual, Outcome 3 Other outcomes - health markers.
Other outcomes - health markers
Study Lipoproteins Haematolog-
ical markers
Pulmonary function Quality of life Other health markers
Benowitz 2012 No significant changes in
any group for HDL cho-
lesterol
No significant changes
in any group for WBC,
haemoglobin or fibrino-
gen
Not reported Not reported Average weight gain
among compliant smok-
ers in the reduced nico-
tine group was 2 kg (sta-
tistically significant),
but no difference be-
tween control and re-
duced-nicotine group
overall. No significant
changes in any group for
blood pressure or
heart rate
Roethig 2008 Greater % increase
for HDL cholesterol in
EHCSS group than in CC
% reduction from base-
line to 12m was greater
in EHCSS group than
Not reported Not reported Not reported
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Other outcomes - health markers
Study Lipoproteins Haematolog-
ical markers
Pulmonary function Quality of life Other health markers
group (P = 0.008), Differ-
ences between groups in
LDL cholesterol not sta-
tistically significant
in CC group for haemo-
globin, haematocrit,
RBC, WBC, neutrophils,
lymphocytes and urine
11-dehydrothrombox-
ane B2 (P < 0.02 in each
case). DIfferences be-
tween groups in CRP, fib-
rinogen and urine 8-epi-
prostaglandin F2α not
statistically significant
Sarkar 2008 Differences between
groups in HDL choles-
terol, LDL cholesterol
and triglycerides not sta-
tistically significant
Differences between
groups in urine mi-
croalbumin, 11-dehy-
drothromboxane B2, 8-
epi-prostaglandin F2α,
fibrinogen, von Wille-
brand factor and CRP
not statistically signifi-
cant, with the exception
of urine microalbumin in
a single group
Not reported Not reported Not reported
 
 
Comparison 9.   Computerized programme to assist smoking reduction versus self-help reduction guide
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Outcomes at long-term follow-up 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Reduction in cigarettes/day of > 50%
of baseline or cessation
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Cessation 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Other outcomes - consumption mark-
ers
    Other data No numeric data
 
 
Analysis 9.1.   Comparison 9 Computerized programme to assist smoking reduction
versus self-help reduction guide, Outcome 1 Outcomes at long-term follow-up.
Study or subgroup Experimental Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
9.1.1 Reduction in cigarettes/day of > 50% of baseline or cessation  
Riley 2002 8/44 9/49 0.99[0.42,2.34]
   
9.1.2 Cessation  
Riley 2002 5/44 3/49 1.86[0.47,7.32]
Favours self-help 100.1 50.2 20.5 1 Favours computerized
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Analysis 9.2.   Comparison 9 Computerized programme to assist smoking reduction
versus self-help reduction guide, Outcome 2 Other outcomes - consumption markers.
Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
Riley 2002 A mean reduction of approx-
imately 10 CPD between pre-
treatment to post-treatment
in both groups, which was es-
sentially maintained over 1
year. Differences in % reduc-
tion from pre-treatment to 6m
(N = 60; 32% for CSGR; 25% for
SER) and to 12m (N = 57; 38%
for CSGR; 35% for SER) were
not significant
Not reported Overall reduction in mean CO
from 22.6 to 19.6 ppm (P <
0.01) from pre- to post-treat-
ment, but no significant effect
of treatment
 
 
 
Comparison 10.   Behavioural reduction advice to assist smoking reduction versus health mailings
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Outcomes at long-term follow-up 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Reduction in cigarettes/day of > 50%
of baseline or cessation
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Cessation 1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Other outcomes - consumption mark-
ers
    Other data No numeric data
 
 
Analysis 10.1.   Comparison 10 Behavioural reduction advice to assist smoking
reduction versus health mailings, Outcome 1 Outcomes at long-term follow-up.
Study or subgroup Treatment Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
10.1.1 Reduction in cigarettes/day of > 50% of baseline or cessation  
Glasgow 2009 41/164 29/156 1.34[0.88,2.05]
   
10.1.2 Cessation  
Glasgow 2009 11/164 7/156 1.49[0.59,3.76]
Favours health mailings 100.1 50.2 20.5 1 Favours reduction advice
 
 
Analysis 10.2.   Comparison 10 Behavioural reduction advice to assist smoking
reduction versus health mailings, Outcome 2 Other outcomes - consumption markers.
Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
Glasgow 2009 No difference between groups
in CPD at 3m (Intervention
mean (SD) 17.2 (9.6); Con-
trol 17.3 (8.7)) or at 12m (15.8
(10.3); 15.3 (9.2)), but both
Not reported Mean (SD) CO levels
At baseline: Intervention (n =
164) 29.8 (13.9); Control (n =
156) 29.8 (14.5)
-
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Other outcomes - consumption markers
Study CPD Cotinine/Thiocyanate CO Other consumption markers
groups had showed "modest
change from baseline" (21.2
(9.4); 20.1 (8.9))
At 12m: Intervention (n = 164)
24.9 (14.0); Control (n = 156)
24.3 (13.8). No significant be-
tween-group difference in the
change from baseline
 
 
A P P E N D I C E S
Appendix 1. Cochrane Register of Studies (CRS) search strategy
#1 MeSH DESCRIPTOR Harm Reduction
#2 Harm Reduction:MH
#3 Harm Reduction:TI,AB,EMT,KY,XKY,KW
#4 MeSH DESCRIPTOR Risk Reduction Behavior
#5 Risk Reduction Behavior:MH
#6 Risk Reduction:TI,AB,EMT,KY,XKY,KW
#7 smoking reduction:TI,AB,MH,EMT,KY,XKY,KW
#8 (reduce* smoking):TI,AB,MH,EMT,KY,XKY,KW
#9 (tobacco harm):TI,AB,MH,EMT,KY,XKY,KW
#10 (cigarette ADJ2 (reduction or reduce*)):TI,AB,MH,EMT,KY,XKY,KW
#11 (controlled smoking):TI,AB,MH,EMT,KY,XKY,KW
#12 MeSH DESCRIPTOR Risk Assessment
#13 Risk Assessment:MH
#14 (electronic nicotine delivery system*):TI,AB
#15 (Potential reduced exposure products OR PREP OR PREPs):TI,AB
#16 (electronic cigar* OR e-cig* OR ecig*):TI,AB
#17 (temporary and (abstinence or abstain*)):TI,AB,MH,EMT,KY,XKY,KW
#18 dual use*:TI,AB,MH,EMT,KY,XKY,KW
#19 smokeless ADJ tobacco:TI,AB,MH,EMT,KY,XKY,KW
#20 (swap or substitut*):TI,AB,MH,EMT,KY,XKY,KW
#21 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19
W H A T ' S   N E W
 
Date Event Description
7 December 2016 Amended Correction: Citation reference changed from Ranstrom 2014 to
Ramstrom 2014 in 'Additional references' section
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H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 3, 2007
 
Date Event Description
13 October 2016 New search has been performed Updated with 6 new studies added. Some data points updated
to ensure reductions over 50% also included participants who
had quit in all cases. We now exclude 1 previously included study
(Pisinger 2005). The study was previously borderline include and
results were not meta-analysed. This was because the study was
not conducted or reported so that participants willing to quit
could be separated from those unwilling to quit in the control
arm.
13 October 2016 New citation required and conclusions
have changed
New interventions added with new associated conclusions at
this update
24 June 2010 New search has been performed Updated with six new studies and published data for one previ-
ously included study. Outcome summaries changed from odds
ratio to risk ratio. No substantial change to conclusions.
28 October 2008 Amended Converted to new review format.
 
C O N T R I B U T I O N S   O F   A U T H O R S
Conception of review: KH, LS, TL (original authors of the protocol for this review).
Study eligibility decisions: AF, JHB, NLH, RB
Data extraction: AF, JHB, NLH, RB
Statistical support & drafting of review tables for secondary outcomes: TRF
Drafting of review: NLH
Review of draW: AF, JHB, RB, TL, TRF
D E C L A R A T I O N S   O F   I N T E R E S T
AF has received personal consultancy fees from the Annals of Internal Medicine to write an independent review of a commissioned article.
JHB has no known conflicts of interest.
NLH is a co-applicant on a completed trial investigating nicotine patch preloading for smoking cessation (not a harm reduction approach).
The nicotine patches were provided free of charge by GlaxoSmithKline; however the trial was funded by the NIHR HTA (09/110/01), and
the running and the reporting of the trial were carried out independently to the funder and treatment provider.
RB has no known conflicts of interest.
TL has no known conflicts of interest.
TRF has no known conflicts of interest.
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S O U R C E S   O F   S U P P O R T
Internal sources• NuHield Department of Primary Care Health Sciences, University of Oxford, UK.
Provides infrastructure for NLH, JHB, RB, TRF, TL, and salary for RB• Public Health, Epidemiology & Biostatistics, University of Birmingham, UK.
Salary and infrastructure support for AF
External sources• National Institute for Health Research, UK.
Salary support for JHB & NLH and infrastructure for the Cochrane Tobacco Addiction Group
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We made the following changes for the 2016 update:
1. Specification that rates of reduction of 50% of baseline CPD or more include those participants who have stopped smoking completely
(this is deemed to be a reduction of 100%);
2. Clearly specified that participants must not be intending to quit at enrolment;
3. Extended the search strategy to include terms relating to outcomes and products more recently adopted as harm reduction aids, such
as temporary abstinence and electronic cigarettes.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Smoking Prevention;  *Tobacco Use Cessation Devices;  Biomarkers  [blood];  Bupropion  [therapeutic use];  Carbon Monoxide  [blood];
  Cotinine  [blood];  Electronic Nicotine Delivery Systems;  Nicotine  [therapeutic use];  Nicotinic Agonists  [therapeutic use];  Randomized
Controlled Trials as Topic;  Smoking  [adverse eHects]  [blood];  Smoking Cessation  [methods];  Tobacco Use Disorder  [*therapy]
MeSH check words
Humans
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